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Chikungunya virus (CHIKV) is an Aedes mosquito-transmitted alphavirus that causes 
epidemics of a debilitating, often chronic polyarthritis in humans. Over five million people in 
Africa and Asia have been infected since 2005, and an outbreak occurred recently in Italy 
demonstrating the potential for a global epidemic. A strong antibody response is elicited during 
infection and the aim of this thesis was to develop a better understanding of how the humoral 
immune response can control CHIKV infection. We identified 230 new anti-CHIKV monoclonal 
antibodies (MAbs) and tested their ability to inhibit infection of strains representing all three 
CHIKV genotypes (East/Central/South African, West African and Asian). We identified 36 of 
these MAbs that inhibit Chikungunya infection; almost half of them are potently neutralizing and 
have EC50 values of less than 15 ng/mL (0.1 nM) against CHIKV strains representing the three 
genotypes. Many of these MAbs exhibit cross-reactivity with a number of related alphaviruses 
including O’nyong’nyong, Ross River, Semliki Forest, Mayaro, Una, Getah, Bebaru, 
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Middleburg, Barmah Forest, Sindbis and Venezuelan equine encephalitis viruses. Four of these 
neutralizing MAbs provided complete protection as prophylaxis in highly susceptible 
immunocompromised mice and mapped to distinct antigenic epitopes on the E1 and E2 structural 
proteins. To define functional epitopes, we selected for escape mutants in vitro for these four 
MAbs. We identified most of these escape mutants in the brains and leg muscle of mice dying 
despite lower dose prophylaxis or monotherapy. The most protective MAb was humanized, 
shown to block viral fusion, and require Fc effector function for optimal activity in vivo. In post-
exposure therapeutic trials, administration of a single dose of a combination of two neutralizing 
MAbs targeting different domains of the E2 surface glycoprotein or targeting both the E1 and E2 
glycoproteins limited the development of resistance and protected immunocompromised mice 
against disease when given even 24 to 36 hours before CHIKV-induced death. These studies 
provide some insight into the location of neutralizing epitopes of CHIKV and how selected pairs 
of highly neutralizing MAbs may be a promising treatment option for CHIKV infection in 
humans.  
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Chapter I 
 
 
Introduction  
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Virology and Structure of Chikungunya Virus  
 
Chikungunya virus (CHIKV) is encoded by an 11.8 kb single-stranded, positive sense 
RNA with two open reading frames (ORF). It is one of 29 alphaviruses and belongs to the 
Togaviridae family of enveloped viruses. The Alphavirus genus is split into the New World 
alphaviruses, which include Eastern, Western, and Venezuelan equine encephalitis viruses 
and the Old World alphaviruses, which are primarily arthitogenic and include CHIKV, 
Sindbis, Semliki Forest, Ross River and O’nyong’nyong viruses [1,2]. There are three 
genotypes of CHIKV: East/Central/South African (ECSA), Asian and West African. Based 
on E1 amino acid sequence analysis, the three genotypes are between 95.2 and 99.8% 
identical [3]. The CHIKV genome is flanked by untranslated regions with a 5' N-methyl 
guanosine cap and polyA tail, between which two ORFs reside. The 5' two-thirds of the 
genome encodes the four non-structural proteins (nsP 1, 2, 3, 4) [4,5]. As shown for other 
alphaviruses, it is predicted that two different non-structural polyproteins are translated. The 
predominant population is nsP123 and a minor amount of nsP1234 is produced when there is 
complete read-through of this ORF. As nsP4 is the RNA polymerase, limiting the production 
of nsP4 can help control RNA replication. These polyproteins are subsequently processed 
into the individual proteins by the nsP2 protease.  The second ORF, which is downstream of 
a separate 26S subgenomic promoter [6], encodes the structural proteins: C (the nucleocapsid 
protein), E3, E2, 6K, and E1. [4,7] 
Of the five structural proteins, the glycosylated envelope proteins E1 and E2 form 
heterodimers in a trimeric array. Eighty such trimers compose the icosahedral lattice which is 
embedded into a host plasma-membrane derived lipid bilayer by a single transmembrane 
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helix for each of E1 and E2. This constitutes the envelope and outermost layer of CHIKV. 
Two-hundred and forty copies of the capsid protein also arrange into an icosahedral structure 
to form the nucleocapsid layer (with T=4 symmetry), within which the ssRNA genome is 
located. [7] 
The E2 precursor protein, p62 is cleaved by the cellular enzyme furin en-route to the 
plasma membrane to yield the mature E2 and E3 proteins. The small protein E3 is composed 
of the 64 N-terminal amino acids of p62 and it remains attached to the virion on some 
alphaviruses [8-10]. Glycoprotein E1 is composed of the N-terminal domain I and domains II 
and III; the fusion loop is located at the tip of domain II. E2 is composed of domains A, B 
and C. Domains III and C are oriented closest to the viral membrane. Recently, the crystal 
structures of CHIKV p62-E1 and mature E3-E2-E1 were solved [8]. E2 covers much of E1 in 
a twisted plate morphology on the viral surface and the fusion loop of E1 lies between the 
groove formed by domains A and B of E2. These studies also indicate that the immature and 
mature forms of the heterodimer are similar, except for the tether region connecting E3 to 
p62, which is disordered in the mature post-furin cleavage form [8]. 
 
Epidemiology 
 
Although Chikungunya virus was first isolated from a febrile patient during an epidemic 
of fever and severe joint pain in Tanzania in 1953 [11-14], based on retrospective case-study 
and phylogenetic analysis, it is estimated that CHIKV has caused disease in Africa and 
Southeast Asia since the late 1700’s. CHIKV has epidemic potential, as reflected by the 
initial description in which it spread from village to village, infecting between 80-90% of the 
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inhabitants [15]. Over the last few decades, CHIKV has re-emerged and periodically caused 
outbreaks across Africa and Asia [1,16]. Significant morbidity has been observed, although 
historically, infection did not cause much mortality. Between 2005 and 2007, however, there 
was an explosive CHIKV epidemic of unprecedented magnitude; it initiated on the coast of 
Kenya in 2004 and spread to the French island of La Reunion (LR), from which it quickly 
dispersed to other Indian Ocean islands, India and many nations in Africa [1,17,18]. The 
ECSA genotype of CHIKV gave rise to this epidemic strain of circulating CHIKV which 
affected over five million people including approximately one third of the population of La 
Reunion island (~300,000 people) [18,19]. Although travelers returning from endemic 
countries to Canada, Europe and the United States have developed Chikungunya disease, 
local epidemics did not occur in these temperate climates. This changed in 2007 with the 
onset of the first European autochthonous epidemic, which caused 229 cases and one fatality 
in Northern Italy [20-22]. Three years later, in 2010, autochthonous cases of Chikungunya 
were reported in France [22,23]. This highlights the possibility of CHIKV spread across the 
world and the importance of developing a vaccine or specific antiviral agents. 
Vertical transmission of CHIKV also has been observed and results in peripartum disease 
(4 days prior to or 2 days post delivery), likely due to intrapartum contamination of fetal 
blood with CHKV, before the mother makes protective antibodies [24,25]. Studies estimate 
that vertical transmission rates are 40 to 50% for viremic mothers [25-27]. These infants 
require intensive care and have a high propensity for developing neurological symptoms. 
[24,25] 
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Clinical Disease of CHIKV infection  
 
The word “chikungunya” comes from the Makonde language spoken in Tanzania and it 
means “that which bends up”; this describes the contorted posture of patients afflicted with 
this disease. Acute infection with CHIKV manifests three to seven days post transmission by 
an Aedes mosquito bite. Symptoms include abrupt onset of a high fever, pruritic, 
maculopapular rash (occurring in 40 to 50% of patients) which extends over the trunk and 
limbs and sometimes the face, polyarthralgias (occurring in >95% of patients) and myalgias 
(occurring in 90% of patients) [4,24,28-31]. Tenosynovitis is another common sign observed 
in the chronic, recurring form of CHIK disease and most often affects the wrists, fingers and 
ankles [32,33]. Polyarthralgias are mainly symmetric and tend to occur in previously injured 
joints or distal joints [24]. Acute symptoms persist for about 14 days but chronic arthralgias 
can linger and are a significant cause of morbidity for weeks to even years. Pain can fluctuate 
in intensity, but does not usually change anatomical location. Joint pain is often debilitating; 
a recent prospective study showed that arthralgias persisted for at least 36 months in over 
60% of a cohort of patients [34]. Rheumatological manifestations, consisting of a febrile 
arthritis predominantly affecting the extremities, were detected 15 months post-infection in 
57% of another cohort of CHIKV patients, although there was no bone or cartilage erosion 
[24,35,36]. Prior osteoarthritis, hypertension or age > 45 were identified as risk factors for 
developing chronic joint manifestations [36]. 
Prior to the Indian Ocean outbreak, CHIKV infection was not associated with mortality 
but in 2005, this and other severe disease manifestations surfaced. During the epidemic, ~250 
deaths were attributed to CHIKV infection on the island of La Reunion, which corresponds 
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to one death per 1,000 infections [37-39]. Patients with atypical presentations, however, had 
a death rate of 10% [26,27]. Some atypical manifestations included neurological 
(encephalitis, meningoencephalitis, seizures, and Guillain-Barre syndrome), cardiac 
(myocarditis, pericarditis, and heart failure) and renal (nephritis and acute renal failure) 
[1,24,26,28,40] signs and symptoms.  
 
Enzootic cycle 
 
CHIKV is transmitted by the Aedes species mosquitoes and is maintained in a sylvatic 
cycle in Africa, where non-human primates and rodents are the reservoirs and forest-dwelling 
mosquitoes (chiefly the Aedes species furcier, taylori, luteocephalus and africanus) and are 
the vectors for transmission. [4,41-43] During epidemics, humans serve as the reservoirs. In 
Asia, there is only mosquito-human-mosquito transmission, as a sylvatic cycle has not been 
documented [24,42]. Aedes aegypti, an urban mosquito that maintains close association with 
humans, is the primary vector in Asia. In comparison, Aedes albopictus was the vector 
primarily responsible for the La Reunion epidemic in 2005-2007 [1,4]. The global 
distribution of Aedes albopictus mosquitoes has spread over the last few decades to include 
all continents, either tropical or temperate, so CHIKV epidemics could theoretically occur 
anywhere. [37] 
An A226V mutation on the E1 glycoprotein served as a gain-of-function adaptive change 
that resulted in enhanced infectivity of Aedes albopictus mosquitoes (via enhanced 
dissemination of the virus from the midgut to secondary organs), which ultimately caused an 
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increase in transmission of CHIKV to humans [4,24,44]. At the beginning of the outbreak, all 
viral isolates possessed A226 on the E1 glycoprotein, whereas by the end of the epidemic 
over 90% of CHIKV isolated from La Reunion had acquired the valine point mutation 
[44,45]. The autochthonous cases of Chikungunya reported in Italy were caused by an 
A226V isolate of CHIKV, but the autochthonous cases in Italy originated from the Asian 
genotype and lacked this mutation [22]. Notably, the ratio of clinical apparent to inapparent 
cases is high for CHIKV; only 3.2% of people tested in one study conducted on La Reunion 
were seropositive for CHIKV yet failed to develop acute symptoms consistent with infection 
[28].  
 
Replication Cycle and Virus Assembly 
 
Although the protein NRAMP was recently discovered as a necessary cell surface factor 
for binding and entry of Sindbis virus, a related alphavirus, a bona fide entry receptor for 
CHIKV has not been defined [46]. The E2 glycoprotein binds to the cell surface and this is 
followed by internalization of CHIKV into endosomes, likely in a clathrin-dependent fashion 
[47]. Upon acidification of the late endosome, the E1-E2 heterodimer dissociates and the E1 
glycoprotein (which is a class II fusion protein) undergoes conformational changes exposing 
the fusion loop [41,48]. E1 rearranges into homotrimers which induce fusion between the 
viral and endosomal membranes, thus releasing the nucleocapsid into the cytoplasm 
[8,10,48]. The CHIKV genome is an infectious RNA and can be translated immediately in 
the cytoplasm [7] without modification. Following translation of the non-structural proteins 
(nsP1, nsP2: the helicase, protease and protein also involved in host transcriptional shut-off, 
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nsP3 and nsP4, the RNA polymerase) and replication of the genome to yield negative sense 
RNA, the 3' 26S subgenomic RNA is produced and translated into a polyprotein, which is 
autoproteolytically cleaved into the five structural proteins that form the virion [4]. After the 
N-terminally located capsid protein is released from this polyprotein, pE2 and E1 are inserted 
into the endoplasmic reticulum, form dimers and passaged through the Golgi apparatus. En 
route to the plasma membrane, furin, a cellular calcium-dependent serine protease processes 
pE2 into E2 and E3. These envelope proteins insert into the plasma membrane [5,38]. 
The nucleocapsid is composed of 80 copies of the capsid protein. It forms independently 
in the cytoplasm and encloses a single copy of viral genomic RNA. CHIKV particles bud 
from the plasma membrane as the nucleocapsid associates with the type I integral membrane 
protein E2. Each budding particle contains 80 surface spikes, each composed of a trimer of 
E1-E2 heterodimers arranged in T=4 quasi icosahedral symmetry [5,8]. 
 
Pathogenesis of CHIKV 
 
 Upon delivery of CHIKV into the skin, the virus spreads into the subcutaneous capillaries 
and predominantly infects fibroblasts in the connective tissue [38,49]. It disseminates 
through the blood to lymph nodes and can infect cells in other target organs, such as the liver, 
spleen, muscle and joints [38,49]. CHIKV does not infect osteoclasts, osteoblasts, 
lymphocytes or dendritic cells and there are contradictory reports on its infectivity of 
monocytes [39,50]. CHIKV also selectively infects muscle satellite cells (but not myocytes), 
endothelial cells and monocyte-derived macrophages. Muscle satellite cell infection has been 
observed in patient biopsies and in vitro [51]. Muscle satellite cell infection is particularly 
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significant because these cells are progenitors for new muscle fibers and augmentation of 
pre-existing muscle fibers; satellite cells will undergo cell division and differentiation after 
exercise or muscle injury. If these muscle stem cells are infected, they may help maintain a 
persistent reservoir of CHIKV in the muscle tissue, which may contribute to recurrent 
episodes of arthralgias and myalgias [51,52].  
CHIKV replicates efficiently in humans and titers can reach 1012 RNA copies/mL in the 
serum of infected patients [53]. Tissues targeted in mouse and primate models and in human 
patients include connective tissue, especially the muscle epimysium, the joint capsule, and 
deep dermis [49,52]. Viral dissemination throughout the body was evidenced in a macaque 
model of CHIKV infection, which recapitulates features of human disease. CHIKV RNA was 
detected in the liver, spleen, lymph nodes and joints of all animals tested in the acute phase 
and infectious CHIKV was still recovered from the spleen, muscle and liver 44 days post 
infection [54]. Persistence of CHIKV antigen was detected in splenic macrophages up to 44 
days post-infection and has been hypothesized to serve as a reservoir for long-term 
persistence of CHIKV [54]. Identifying a potential chronic reservoir of CHIKV may be very 
important for understanding the pathophysiology underlying chronic disease. Macrophages 
may contribute to this reservoir; CHIKV was detected 18 months post-infection in the peri-
vascular synovial macrophages of one patient [53]. Additionally, Binadarit (an inhibitor of 
MCP-1) was shown to ameliorate arthritis-like disease symptoms in mice [55]. MCP-1 
(monocyte chemotactic protein 1) is a crucial recruitment factor for macrophages into 
inflamed sites and is unregulated in both the serum and tissue of CHIKV-LR infected mice 
and acutely infected patients [53,55].  
10 
 
In mouse models of CHIKV disease, lethality to CHIKV infection is both age and 
IFNAR status-dependent [49]. IFNAR-/- C57BL/6 mice are highly vulnerable and will die 
three days post intradermal infection with 10 PFU CHIKV-LR. Similarly, 6 day old C57BL/6 
wild-type neonates will uniformly die when administered 106 PFU of CHIKV-LR 
intradermally , but if they are allowed to age just three more days, 60% will survive and at 12 
days of age these mice are no longer susceptible to death following CHIKV infection [49]. 
 Although CHIKV is an Old World arthritogenic virus, it has been shown to cause CNS 
disease, (encephalitis and meningitis), especially in neonatal patients and in mouse models 
[26]. CHIKV infects the choroid plexus and ependymal cells and the meninges but not brain 
endothelial cells, neurons, or microglia [49].  
 
 
Antibody-mediated Protection against CHIKV 
 
 
 Polyclonal antibody response to CHIKV 
Although the innate immune response plays an essential early role in protection against 
CHIKV infection, the antibody response against this virus is rapid and also important. IgG 
can be detected 3-8 days post symptom onset, even as early as 2 days post symptoms in some 
patients [31,56,57]. Many patients in a study of travelers returning back to Europe from the 
Indian Ocean region were positive for IgM antibody at the onset of symptoms (day 1) and all 
patients positive for CHIKV infection had both IgG and IgM by day 5 post symptom onset 
[57]. The rapid kinetics of antibody production may, in part, be attributed to the high CHIKV 
viremia, which results in a significant antigen load prior to symptom onset,[57]. Although 
IgM titers usually last for 1-3 months post-infection [31]; the persistence of IgM as late as 18 
11 
 
months after acute CHIKV infection in some patients suggests possible viral persistence 
[35,58].  
The importance of the antibody response in clearing CHIKV infection was demonstrated 
in µMT mice that lack mature B cells. These mice sustain significantly higher CHIKV titers 
that start earlier in the course of disease, and they experience more joint swelling than wild 
type mice. Chronic infection occurred in µMT mice; viremia persisted for 79 days and has 
lasted as long as 402 days in surviving mice [59].  
Passive transfer of polyclonal immunoglobulins from convalescent CHIKV infected 
patients protect against death of CHIKV-infected immunocompromised or neonatal mice. 
This demonstrates the neutralizing and protective potential of immune sera [60]. In a separate 
study, non-human primates were vaccinated with virus-like-particles (VLPs) containing 
CHIKV structural proteins; two milligrams of purified IgG from these animals was delivered 
passively to IFNAR-/- mice; this protected against death and viremia [61]. This further 
suggests that antibodies in immune sera alone can protect against CHIKV infection.  
 
Monoclonal antibody response to CHIKV 
Only a few studies involving CHIKV MAbs have been reported. Mouse MAbs against 
CHIKV that cross-react to O’nyong’nyong virus, some of which inhibit haemagglutination of 
both CHIKV and O’nyong’nyong virus, were identified in 1995 [62]. Years later, another 
study identified three antibodies that were shown to react with the E2 glycoprotein of 
CHIKV; neutralization potential was not determined [63].  
Two neutralizing human MAbs (8B10 and 5F10) were identified from immortalized 
peripheral blood mononuclear cells (PBMCs) harvested from a patient previously infected 
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with CHIKV [64]. Escape mutants that were less sensitive to neutralization by these MAbs 
were isolated under antibody passage, but they still partially neutralized at higher 
concentrations of MAb [65]. The potential of one of these mutations (E2-R82G) to enhance 
potential cell-cell transmission of CHIKV was considered [65], however, further study is 
warranted.  Although a high dose (250 µg) of 8B10 was protective against death in AGR129 
mice (lacking the interferon α/β/γ receptor) when administered six hours before CHIKV 
infection, neither 8B10, 5F10 or the combination of these MAbs was able to prevent death 
therapeutically even when delivered just eight hours post infection [66]. 
Studies investigating the human antibody response to CHIKV have suggested that the 
dominant, neutralizing antibodies produced are mostly directed against the E2 glycoprotein 
and the major isotype represented is IgG3 [59,67-69]. One study found that neutralizing 
human antibodies primarily target a linear peptide consisting of 18 amino acids located at the 
N-terminus of E2 which they denoted E2EP3 [67]. In a different cohort consisting of nine 
patients, antibodies targeting nsP3 and E2 were identified 2-3 months post-infection, but only 
antibodies against E2 persisted 21 months post infection [69].  
Patient studies also have correlated a more severe, acute disease with early, high viremia 
but this group also developed an early IgG3 response and completely cleared CHIKV 
infection without persistent arthralgia [68]. Early IgG3 responders were defined as patients 
producing IgG3 by 7- 10 days after the onset of infection and while no one in this group 
maintained chronic CHIKV symptoms, 30% of late IgG responders developed persistent 
arthrlagias [68].  
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Rationale 
 This work was initiated towards the end of one of the largest recorded CHIKV 
epidemics in history, when little was known about the immune response to CHIKV. We 
sought to generate a novel panel of anti-CHIKV MAbs because we were interested in 
developing a better understanding of how the humoral immune system restricts CHIKV 
infection. To encourage the diversity of epitopes targeted by MAbs, we immunized mice 
with CHIKV-LR and boosted four mice with either VLPs [61], E2 glycoprotein or CHIKV-
LR. We aimed to identify highly neutralizing MAbs, determine what viral epitopes they 
targeted, identify mechanisms of neutralization and determine if these MAbs are protective in 
animal models. There is currently no licensed, human vaccine for CHIKV but insight into 
neutralizing viral epitopes is imperative for directed vaccine design so we hoped to learn 
more about neutralizing CHIKV epitopes and the molecular basis of neutralization. 
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ABSTRACT 
 Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes 
global epidemics of a debilitating polyarthritis in humans. As there is a pressing need for 
the development of therapeutic agents, we screened 230 new mouse anti-CHIKV 
monoclonal antibodies (MAbs) for their ability to inhibit infection of all three CHIKV 
genotypes. Four of 36 neutralizing MAbs (CHK-102, CHK-152, CHK-166, and CHK-
263) provided complete protection against lethality as prophylaxis in highly susceptible 
immunocompromised mice lacking the type I IFN receptor (Ifnar-/-) and mapped to 
distinct epitopes on the E1 and E2 structural proteins. CHK-152, the most protective 
MAb, was humanized, shown to block viral fusion, and require Fc effector function for 
optimal activity in vivo. In post-exposure therapeutic trials, administration of a single 
dose of a combination of two neutralizing MAbs (CHK-102 + CHK-152 or CHK-166 + 
CHK-152) limited the development of resistance and protected immunocompromised 
mice against disease when given 24 to 36 hours before CHIKV-induced death. Selected 
pairs of highly neutralizing MAbs may be a promising treatment option for CHIKV in 
humans. 
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AUTHOR SUMMARY 
 Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes 
outbreaks of polyarthritis in humans, and is currently a threat to spread to the United 
States due to the presence of its mosquito vector, Aedes albopictus. At present, there is no 
licensed human vaccine or therapeutic available to protect against CHIKV infection. The 
primary goal of this study was to develop an antibody-based therapeutic agent against 
CHIKV. To do this, we developed a panel of 230 new mouse anti-CHIKV MAbs and 
tested them for their ability to neutralize infection of different CHIKV strains in cell 
culture. We identified 36 MAbs with broad neutralizing activity, and then tested several 
of these for their ability to protect immunocompromised Ifnar-/- mice against lethal 
CHIKV infection. In post-exposure therapeutic trials, administration a single dose of a 
combination of two neutralizing MAbs limited the development of resistance and 
protected Ifnar-/- mice against disease even when given just 24 to 36 hours before 
CHIKV-induced death. Analogous protection against CHIKV-induced arthritis was seen 
in a disease model in wild type mice. Our data suggest that pairs of highly neutralizing 
MAbs may be a therapeutic option against CHIKV infection. 
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INTRODUCTION 
 Chikungunya virus (CHIKV) infection causes a severe febrile illness in humans 
that is characterized by a debilitating polyarthritis, which can persist for months and 
cause significant morbidity [1,2]. There are three genotypes of CHIKV: Asian, 
East/Central/South African (ECSA), and West African [3-5], with 95.2 to 99.8% amino 
acid identity [4]. The CHIKV strains from the recent epidemics belong to the ECSA 
genotype and have affected millions in Africa and the Indian subcontinent [3,6]. Imported 
cases in the United States and outbreaks in Europe highlight the threat of CHIKV to 
developed countries [7]. Currently, there are no approved vaccines or therapeutics for 
CHIKV [8]. 
 CHIKV is an enveloped alphavirus of the Togaviridae family that enters cells via 
receptor-mediated internalization and a low pH-triggered type II membrane fusion event 
in early endosomes. The mature virion is comprised of three structural proteins: a 
nucleocapsid protein and two glycoproteins, E1 and E2, where E2 functions in 
attachment to cells and E1 participates in virus fusion. Each 700 Å CHIKV virion 
contains 240 copies of the envelope and capsid proteins, which are arranged in T=4 
quasi-icosahedral symmetry. E1-E2 heterodimers assemble into 80 trimeric spikes on the 
virus surface [9]. X-ray crystallographic structures of the precursor pE3-E2-E1, mature 
E2-E1, and E1 proteins [10-13] have elucidated the architecture of the glycoprotein shell. 
The E1 ectodomain consists of three domains. Domain I (DI) is located between DII and 
DIII, the latter of which adopts an immunoglobulin-like fold. The fusion peptide is 
located at the distal end of DII. E1 monomers lie at the base of the surface spikes and 
form a trimer around each of the icosahedral axes. E2 localizes to a long, thin leaf-like 
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structure on the top of the spike. The mature E2 protein contains three domains with 
immunoglobulin-like folds: the N-terminal domain A, located at the center; domain B at 
the tip; and the C-terminal domain C, located proximal to the viral membrane.  
 Mouse models have been developed for CHIKV infection. Newborn outbred and 
inbred mice are vulnerable to severe CHIKV infection with viral replication observed in 
muscle, joint, and skin [14,15]. Adult mice with defects in type I interferon signaling 
(Ifnar-/- mice) develop lethal disease, with muscle, joint, and skin appearing as the 
primary sites of infection [15]. CHIKV infection of juvenile C57BL/6 mice by a 
subcutaneous route results in metatarsal foot swelling with histological evidence of 
arthritis, tenosynovitis and myositis [16,17]. 
 Passive transfer of MAbs or immune sera can protect animals against infection of 
alphaviruses including Sindbis (SINV), Semliki Forest (SFV), and Venezuelan equine 
encephalitis (VEEV) viruses [18-25]. Immune -globulin from human donors in the 
convalescent phase of CHIKV infection exhibited neutralizing activity in vitro and had 
partial therapeutic efficacy in Ifnar-/- and neonatal wild type mice when administered up 
to 24 hours after infection [26]. Although mouse and human MAbs that neutralize 
CHIKV infection have been reported [27,28], their post-exposure efficacy against lethal 
infection in vivo has not been clearly established [29]. 
 Here, we investigated the molecular basis of antibody-mediated neutralization of 
CHIKV using a panel of 230 newly generated, cloned MAbs. CHK-152 protected mice 
against CHIKV-induced mortality and disease. The inclusion of a second MAb (CHK-
166 or CHK-102) prevented the emergence of viral resistance and extended the treatment 
window in Ifnar-/- mice up to 24 to 36 hours prior to death of the animals. Our results 
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suggest that combination therapy with selected neutralizing MAbs has potential for 
treatment of CHIKV infection in humans. 
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RESULTS 
 Generation of MAbs. We generated a panel of neutralizing MAbs against 
CHIKV as a first step towards a possible therapy in humans. We infected adult C57BL/6 
mice deficient for interferon regulatory factor 7 (Irf7-/-) with 104 PFU of the La Reunion 
2006 OPY-1 strain of CHIKV (CHIKV-LR); these mice were boosted with CHIK virus-
like particles [30], soluble recombinant CHIKV E2 protein, or live CHIKV-LR. We 
immunized Irf7-/- rather than wild type (WT) mice, as CHIKV replicated to higher titers, 
induced stronger neutralizing antibody responses, yet did not cause lethal infection in 
these innate immune-deficient animals ([31], and data not shown). We screened four 
independent myeloma cell-splenocyte fusions for binding of hybridoma supernatants to 
CHIKV-LR infected cells (Fig S1) and cloned 230 CHIKV-specific MAbs for further 
analysis (Table S1 in Text S1). Using a single endpoint neutralization assay, we 
identified 36 MAbs with inhibitory activity against infection of CHIKV-LR in BHK21-
15 cells (data not shown).  
 Neutralizing activity. To assess the inhibitory potential of our anti-CHIKV 
MAbs against the homologous CHIKV-LR and representative strains from the Asian and 
West African genotypes (RSU1I and bH35respectively), we performed focus reduction 
neutralization tests (FRNTs) on Vero cells. We determined the concentration of MAb that 
reduced the number of foci of infection by 50 or 90% (EC50 and EC90 values, Fig 1A 
and B, and Table 1). CHK-152 was the most strongly neutralizing MAb we identified; 3 
and 15 ng/ml of this MAb prevented 50 and 90% of CHIKV infection against all three 
CHIKV genotypes (Fig 1C). Ten other MAbs inhibited CHIKV infection with EC50 
values of <10 ng/ml against all three genotypes, and many others inhibited all three 
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strains similarly, with a few exceptions. For example, CHK-9 failed to neutralize the 
Asian strain to the same extent as the West African or La Reunion (ECSA genotype) 
strains (Fig 1D), whereas CHK-151 inhibited infection of the Asian strain better than the 
others (Table 1). Also, for reasons that are unclear, some neutralizing MAbs (e.g., CHK-
143, CHK-264, and CHK-269) were incapable of inhibiting all viruses (EC90 > 10,000 
ng/ml) in this assay, even at high MAb concentrations. 
 We speculated that some MAbs might show cell type-dependent neutralization if 
they blocked attachment to cell type-specific factors. To test this hypothesis, we assessed 
MAb neutralization of CHIKV-LR infection in cells of another species, NIH 3T3 mouse 
fibroblasts (Table 1). For most MAbs, the EC50 values were comparable to those 
achieved with Vero cells. However, two MAbs (CHK-96 and CHK-176) showed a 12 to 
250-fold reduction (P < 0.05) in neutralizing activity on NIH 3T3 compared to Vero 
cells; although further study is warranted, these MAbs may block a step in the entry 
pathway that varies among different cell types.  
 Prophylaxis studies. To evaluate whether neutralizing MAbs protect against 
CHIKV infection in vivo, we initially used a stringent test model: prevention of lethal 
infection in immunodeficient Ifnar-/- C57BL/6 mice. One hundred micrograms of 14 
different MAbs with strong, modest, or poor neutralizing activity were administered to 
Ifnar-/- mice one day prior to CHIKV-LR infection. As seen previously [15], all Ifnar-/- 
mice died by day 4 after infection when treated with saline or a negative control MAb 
(Fig 2A, and data not shown). Strongly neutralizing (e.g., CHK-102, CHK-152, and 
CHK-263) and one moderately inhibitory (CHK-166) MAb protected 100% of mice from 
lethal infection (P < 0.0001). In comparison, and somewhat surprisingly, CHK-95, a 
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potently neutralizing MAb of the same IgG2c isotype, protected only 12% of mice from 
death. The other MAbs tested conferred intermediate levels of protection (Fig 2A). Thus, 
although several strongly neutralizing MAbs prevented against lethal CHIKV infection in 
Ifnar-/- mice, in vitro neutralization activity per se did not directly correlate with 
protection. To define the relative potency of the four MAbs that completely prevented 
lethal disease, we administered a lower (10 µg) dose. Whereas CHK-152 and CHK-263 
still protected most mice from lethal infection, CHK-102 and CHK-166 protected to a 
lesser degree or only prolonged survival (Fig 2B). Consistent with their ability to protect 
against lethal infection, passive transfer of CHK-102, CHK-152, CHK-166, and CHK-
263 MAbs all markedly reduced viral loads in serum, spleen, liver, muscle, and brain at 
48 hours after infection relative to a non-binding isotype control (DENV1-E98) MAb 
(Fig 2C-G). The level of protection afforded by CHK-102, CHK-152, CHK-166, and 
CHK-263 MAbs, however, did not correlate directly with their binding strength to 
CHIKV surface glycoproteins (Fig S2). 
 Although a stringent test of MAb protection, CHIKV-infected Ifnar-/- mice do not 
develop the arthritis observed in humans. To evaluate this, we utilized a WT C57BL/6 
mouse model in which inoculation of CHIKV into the footpad results in localized 
swelling and induction of arthritis and fasciitis within the foot and ankle [16,17], 
although infection does not cause lethality. Pretreatment of mice with either 100 µg of 
CHK-102 or CHK-152 completely protected against CHIKV-induced swelling, compared 
to control animals, which developed clinically apparent swelling (data not shown). While 
CHIKV infected control animals developed inflammatory arthritis in the ankle and foot, 
CHK-102 or CHK-152 MAb treated animals had normal appearing joint tissues (Fig 2H). 
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Mechanism of neutralization. Antibody neutralization of enveloped viruses can 
occur by inhibiting attachment, internalization, and/or fusion [32,33]. To determine how 
many of our most protective MAbs inhibited infection in cell culture, we performed pre- 
and post-attachment neutralization assays [34,35]. Anti-CHK MAbs were incubated with 
CHIKV before or after virus binding to cells, and infection was measured. As expected, 
all MAbs efficiently neutralized infection when pre-mixed with virus (Fig 3A). While 
CHK-102, CHK-152, CHK-166, and CHK-263 also inhibited CHIKV infection when 
added after virus adsorption to the cell surface, suggesting that at least part of their 
blocking activity was at a post-attachment step, differences in the extent of neutralization 
were noted in this context for several MAbs. CHK-152 completely neutralized all 
CHIKV virions without a resistant fraction when added post-attachment. When studies 
were repeated with eight other neutralizing MAbs that showed pre-exposure protection in 
vivo, no other MAb inhibited infection completely when added after virus adsorption to 
the cell. As expected, an isotype control MAb (DENV1-E98) and a non-neutralizing anti-
CHK MAb (CHK-84) had no inhibitory effects in this assay (Fig S3). 
 Blockade of viral fusion. Since CHK-152 neutralized infection efficiently at a 
post-attachment step, we investigated whether it blocked fusion using a viral fusion from 
without (FFWO) assay [36]. CHIKV was adsorbed to Vero cell monolayers on ice and 
then treated with MAbs. Fusion at the plasma membrane was triggered after a brief 
exposure to low pH buffered medium at 37°C. Subsequently, cells were incubated in the 
presence of 20 mM NH4Cl to prevent CHIKV fusion via canonical endosomal pathways. 
As expected, at 14 hours after initial treatment, CHIKV infection was not observed when 
adsorbed virus was incubated at neutral pH (Fig 3B). In comparison, in the absence of 
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MAb or in the presence of a control MAb, a short exposure of cell surface-adsorbed virus 
to acidic pH resulted in infection and CHIKV-antigen positive cells. Notably, CHK-152 
completely inhibited (P < 0.0001) plasma membrane fusion and infection, whereas other 
anti-CHIKV neutralizing MAbs showed significant yet incomplete inhibition in this assay 
(Fig 3B and C). These studies suggest that CHK-152 efficiently neutralizes infection by 
preventing the structural changes on the virion necessary for viral fusion with host cell 
membranes. 
We utilized a model liposome fusion assay with pyrene-labeled virus [37,38] to 
confirm these results. Pyrene-labeled CHIKV was pre-incubated with different 
concentrations of MAb, mixed with liposomes at 37°C, and fusion was triggered by 
addition of a low-pH buffer [37]. In the absence of MAb or in the presence of 10 nM (1.5 
µg/ml) of a non-binding control MAb, fusion was complete within seconds of 
acidification. In contrast, pre-incubation of virus with increasing doses of CHK-152 
inhibited fusion (Fig 3D and E). Thus, CHK-152 can block low-pH-induced fusion of 
virus with liposomes. 
 The effector functions of CHK-152 contribute to protection in vivo. To define 
additional mechanisms by which our most strongly protective MAb (CHK-152) conferred 
protection in vivo, we generated a chimeric mouse-human CHK-152 (ch-CHK-152) as 
well as an aglycosyl variant (ch-CHK-152 N297Q) that lacks the ability to engage C1q or 
Fc-γ receptors; this mutation does not affect the ability to bind the neonatal Fc receptor 
(FcRn) or half-life of antibody in mouse serum [39]. The affinity of ch-CHK-152 and ch-
CHK-152 N297Q binding to purified pE2-E1 was measured by surface plasmon 
resonance (SPR) and compared to the parent murine MAb. Notably, ch-CHK-152, ch-
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CHK-152 N297Q, and the murine CHK-152 all had similar affinity (KD of 3 to 4 nM) 
(Fig 4A and data not shown) and neutralizing activity in cell culture (Fig 4B). As 
expected, ch-CHK-152 N297Q failed to bind efficiently to soluble Fc-γ receptors or C1q 
(Fig 4C). 
 We transferred ch-CHK-152 and ch-CHK152 N297Q to Ifnar-/- mice prior to 
infection. Although high doses (100 µg) of ch-CHK-152 and ch-CHK-152 N297Q 
provided similar protection against CHIKV infection (data not shown), lower doses (10 
µg) of the aglycosyl variant were less protective; whereas 62% of the mice receiving ch-
CHK152 N297Q survived, all Ifnar-/- mice given ch-CHK-152 MAb remained alive (Fig 
4D, P < 0.05). When parallel studies were performed with WT C57BL/6 mice and MAb 
was administered 18 hours after infection, ch-CHK-152 N297Q also provided less 
protection against arthritis compared to ch-CHK-152 (Fig 4E). These data suggest that 
the Fc effector interactions contribute to the potency of CHK-152 in mice. 
 Humanization of CHK-152. We humanized CHK-152 as a first step towards a 
MAb therapeutic (see Supplemental Methods). The affinity for pE2-E1 and neutralizing 
activity of the hu-CHK-152 were similar to mouse CHK-152 (Fig S4A and B). Hu-CHK-
152 also protected Ifnar-/- mice (P > 0.0001) when a single dose (10 or 100 µg) was 
administered one day before infection (Fig S4C). 
 Therapeutic studies. To define the therapeutic potential of our most protective 
MAbs, a single dose (100 µg) was administered to Ifnar-/- mice 24 hours after CHIKV 
infection (Fig 5A). Whereas CHK-152 and 166 protected 58% and 63% of mice from 
death, respectively (P < 0.0001), CHK-263 and CHK-102 had less activity although both 
MAbs increased the median survival time (7 days versus 4 days with the control DENV1-
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E98 MAb, P < 0.0006). Administration of CHK-152 at 12 or 18 hours post infection also 
protected WT mice from CHIKV-induced swelling and arthritis (Fig 5B and Fig 4E).   
 We next tested the activity of combinations of the most protective neutralizing 
MAbs in Ifnar-/- mice. Remarkably, administration of 50 µg each (100 µg total dose) of 
CHK-102 + CHK-152, CHK-263 + CHK-152, or CHK-166 + CHK-152 at 24 hours post 
infection completely prevented mortality in all animals (Fig 5A, P < 0.0001 for MAb 
combinations). This observation was not true for all MAb combinations, as 
administration of 50 µg each of CHK-102 + CHK-263 provided substantially less 
protection with a 14% survival rate. We then performed a more stringent test in which 
100 µg each (200 µg total) of our most protective combinations was delivered as a single 
dose at 48 hours post-infection (Fig 5C). Treatment with CHK-102 + CHK-152 or CHK-
166 + CHK-152 protected 62% of the Ifnar-/- mice (P < 0.003) and the combination of 
CHK-263 + CHK-152 functioned almost as well, with 50% of animals surviving (P < 
0.03). To define the limits of protection in Ifnar-/- mice, which all succumb to CHIKV 
between days 3 and 4, therapy was initiated at 60 and 72 hours after infection. At 60 
hours after infection, Ifnar-/- mice receiving 250 µg each of CHK-102 + CHK-152 or 
CHK-166 + CHK-152 had survival rates of 28 and 71%, respectively (Fig 5D, P = 0.03 
and P = 0.004). Nonetheless, when combination therapy was given at 72 hours after 
infection, a time when overt disease was present, no survival benefit was conferred. Thus, 
combination MAb therapy is superior to monotherapy in protecting against lethal CHIKV 
infection in highly immunocompromised mice.   
 Functional interaction of MAbs. To begin to understand the basis for enhanced 
in vivo activity, we assessed whether CHK-152 and selected MAbs could bind 
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simultaneously to the CHIKV virion. We developed a competition ELISA in which 
virions were captured by a mouse MAb (CHK-65), and then incubated with increasing 
concentrations of CHK-102, CHK-152, CHK-166, or CHK-263 mouse MAbs. After 
washing, hu-CHK-152 MAb was added, and binding was assessed. While pre-bound 
mouse CHK-152 competed against hu-CHK-152 binding as expected, CHK-102, CHK-
166, and CHK-263 minimally competed hu-CHK-152 binding (Fig S5A), suggesting 
their epitopes largely were distinct. However, addition of CHK-102, CHK-166, or CHK-
263 failed to augment the inhibitory activity of CHK-152 when neutralization was 
measured in cell culture (Fig S5B), as no synergy was observed. 
Neutralization escape mutants. To identify epitopes targeted by the therapeutic 
MAbs, we generated escape mutants in cell culture. After sequential virus passage under 
CHK-102, CHK-152, CHK-166, or CHK-263 selection, CHIKV became resistant to 
neutralization by these MAbs (Fig 6A-D). We assessed whether the escape variants 
generated in the presence of one MAb remained sensitive to neutralizationby the other 
MAbs. The CHK-152 escape variant was neutralized efficiently by CHK-102, CHK-166, 
and CHK-263 (Fig 6B, Table S2 in Text S1, and data not shown), and analogously the 
CHK-166 escape variant was inhibited by CHK-102, CHK-152, and CHK-263 (Fig 6C, 
and data not shown). In contrast, CHK-102 and CHK-263 escape variants reciprocally 
were resistant, suggesting their epitopes were the same or overlapping (Fig 6A and D); 
however, CHK-102 and CHK-263 escape variants remained sensitive to neutralization by 
CHK-152 and CHK-166. Notably, selection with combinations of MAbs (e.g., CHK-102 
+ CHK-152) failed to produce escape variants despite several independent attempts (data 
not shown).  
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To identify the mutations that conferred resistance, we sequenced plaque-purified 
escape variants (Table 2, top). Six of eight sequences from CHK-102 escape variants 
contained an L210P mutation in the E2 protein; the remaining two sequences had a 
G209E mutation in E2. For CHK-152 resistant variants, all sequences (9 of 9) contained a 
D59N mutation in E2 and two contained a second A89E substitution in E2. For CHK-
263, 3 of 4 escape variants had a K215E change in E2, whereas 1 of 4 had mutations in 
E2 at G209E. All escape variants (14 of 14) of CHK-166 had a single K61T mutation in 
the E1 protein.  
To verify the amino acid changes that conferred MAb resistance in vitro, we 
introduced several of these substitutions into a chimeric SFV-GFP-CHIKV cDNA 
comprised of SFV non-structural genes, a GFP reporter gene, and the CHIKV structural 
genes (T. Lin, K. Dowd, and T. Pierson, unpublished results). Parental and SFV-GFP-
CHIKV with single amino acid mutations were analyzed for neutralization by CHK-102, 
CHK-152, CHK-166, and CHK-263 (Fig 6E-H). Consistent with our sequencing results, 
viruses encoding mutations in E2-G209 and E2-L210 were resistant to CHK-102, 
changes in E2-D59 conferred resistance to CHK-152, substitutions in E1-K61 resulted in 
resistance to CHK-166, and mutation of E2-G209 and E2-K215 caused resistance to 
CHK-263. However, introduction of E2-A89E (which was present in 2 of 9 clones) failed 
to affect the neutralizing activity of CHK-152.  
In addition to selecting escape variants in cell culture, we harvested organs from 
the few mice that became ill after infection despite single MAb treatment (Table 3, 
bottom). In these moribund Ifnar-/- mice, CHIKV was present in the brain and muscle but 
absent from the spleen or liver (data not shown). This in vivo-derived virus was tested for 
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MAb resistance and sequenced. For mice receiving a 10 µg dose of CHK-102 as 
prophylaxis, resistant variants with a L210P mutation in E2 were obtained. For mice 
receiving CHK-263 or CHK-102 at 24 hours post infection, resistant viruses with a 
G209E mutation in E2 were identified. None of the animals that were pre-treated with 10 
µg of CHK-166 developed escape mutants, as the virus harvested from all 3 mice tested 
retained sensitivity to CHK-166 (data not shown). However, in one animal receiving 
CHK-166 at 24 hours post infection, a single resistant virus with a G64S substitution in 
the E1 gene was recovered (Fig S6). For mice receiving a 10 µg dose of hu-CHK-152 as 
prophylaxis, partially resistant viruses with N231D and K233E mutations in E2 were 
isolated and confirmed by reverse genetics using the chimeric SFV-GFP-CHIKV 
infectious clone (Fig S7). In comparison, when CHK-152 was given as a therapeutic, a 
single mutation at D59N in E2 was obtained in 4 of the 5 mice tested, with a K233T 
mutation in virus from the remaining animal. For animals treated at 48 hours with 
combination MAb therapy, all recovered viruses remained sensitive to CHK-152 yet 
showed partial resistance to CHK-102 or CHK-166 (Fig S8). Mutations in E2 (N332I, 
CHK-166 + CHK-152) were identified. Comparison of 140 available E1 and E2 
sequences from historical and circulating CHIKV strains in a public database 
(http://www.viprbrc.org/) revealed nearly complete conservation of the residues in which 
escape mutants were selected: E1-K61, 100%; E1-G64, 100%; E2-D59, 100%; E2-G209, 
100%; E2-L210, 99.3%; E2-K215, 100%; E2-N231, 100%; and E2-K233, 99.3%. 
To define spatially the location of the amino acids that conferred resistance to our 
highly protective MAbs, these residues were mapped onto the existing CHIKV protein 
crystal structures [10] (Fig 6I, left). Amino acids that conferred neutralization escape to 
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CHK-102 and CHK-263 were located in the B domain of E2. The residues that 
modulated CHK-152 neutralization mapped to the A domain of E2. In contrast, CHK-166 
recognized amino acids on DII of E1, adjacent to the fusion loop. All amino acids that 
conferred neutralization escape appear solvent accessible and highly exposed when 
docked onto the E2-E1 spike (Fig 6I, right).  
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DISCUSSION 
 We set out to identify MAbs with the greatest therapeutic activity against CHIKV 
in mice as a first step toward generating an immunotherapy for humans. Thirty-six MAbs 
with neutralizing activity against CHIKV-LR were identified, the majority of which also 
inhibited infection of strains corresponding to the two heterologous CHIKV genotypes. 
Although all fourteen of the selected anti-CHIKV MAbs improved outcome in vulnerable 
Ifnar-/- mice, only four of these (CHK-102, CHK-152, CHK-166, and CHK-263) 
completely prevented lethality when administered as prophylaxis. CHK-152 provided the 
greatest benefit as post-exposure therapy, although by itself, the window of treatment 
activity was limited in the Ifnar-/- mouse model. While addition of a second MAb (CHK-
102, CHK-166, or CHK-263) failed to enhance CHK-152 neutralization in vitro, it 
limited the development of viral resistance in vitro and in vivo. Remarkably, 
combinations of CHK-102 + CHK-152 or CHK-166 + CHK-152 protected Ifnar-/- mice 
against mortality even when a single dose was administered 24 to 36 hours prior to the 
death of untreated or isotype control MAb-treated animals.   
 In comparison to the highly therapeutic activity of 0.5 mg of CHK-152 + CHK-
166, a single 25 mg dose of immune IgG purified from a convalescent human subject 
protected only 50% of Ifnar-/- mice when administered 24 hours after CHIKV infection 
[26]. The administered dose of neutralizing antibody likely is critical to post-exposure 
treatment of CHIKV infection because of the high viral burden [14,16,17,40]. A high 
viral load impacts therapeutic activity of antibodies as it (a) increases the chance for pre-
existing or selected resistant variants to emerge through quasispecies [28,41]; and (b) 
results in a low relative fractional occupancy of binding to any individual virion, which 
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allows antibodies recognizing key epitopes to fall below their stoichiometric threshold of 
neutralization [42]. Although there is extensive literature on the protective efficacy of 
MAbs or immune sera against alphavirus infection [18-25], no prior study has 
demonstrated reduced CHIKV-induced mortality with MAbs. Although a recent study 
showed that combination post-exposure therapy with two human anti-CHIKV MAbs 
(5F10 and 8B10, 250 µg each at + 8 h) prolonged survival of AG129 (Ifnar-/- x Ifngr-/-) 
mice by ten days, they failed to prevent lethal infection [29]; the basis of this treatment 
failure remains unclear but could reflect the lower neutralizing potency of the MAbs 
(compared to CHK-152), rapid emergence of resistant mutants, or the relative 
susceptibility of the immunocompromised mouse host. In comparison, a neutralizing 
MAb (UM 5.1) administered two days after SFV infection completely protected 
immuocompetent BALB/c mice [43].  
 Why were some combinations of two MAbs effective in vivo? (a) Pairs of MAbs 
may show neutral, additive, or synergistic effects on neutralization. Positive antiviral 
effects could occur through cooperative binding or by trapping CHIKV in conformations 
that makes it less competent to bind a receptor or fuse with host membranes. Nonetheless, 
when we added increasing concentrations of CHK-102, CHK-166, or CHK-263 to CHK-
152, we failed to observe synergy. (b) Certain MAb combinations could prevent the 
emergence of resistance due to the low frequency of two escape mutations occurring 
simultaneously in a single replication cycle. Although we could readily select for 
neutralization escape against a single MAb in vitro and in vivo, we failed to isolate 
resistant mutants against CHK-152 when two MAbs (e.g., CHK-102 + CHK-152) were 
combined. However, some viruses from moribund animals treated with combination 
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MAb therapy showed reduced sensitivity (up to 200-fold) to the other MAb (e.g., CHK-
102) in the pair. In comparison, when mice were treated with a combination of 50 µg 
each of CHK-102 + CHK-263, we failed to observe the same survival benefit that was 
conferred by the combinations of CHK-102, CHK-166, or CHK-263 with CHK-152. 
Since CHK-102 and CHK-263 appear to share overlapping footprints on domain B of E2, 
this particular MAb combination may fail to prevent the rapid emergence of escape 
mutants relative to others targeting distinct epitopes on E1 and E2 proteins. (c) 
Combinations of MAbs could select for resistant viruses that have reduced fitness [44], 
and thus are less pathogenic in vivo. Virulence studies with CHIKV encoding selected 
single and double mutations are planned to evaluate this possibility. 
 We localized the epitopes of our four highly protective MAbs using neutralization 
escape selection, sequencing, and reverse genetics. CHK-152, which blocked viral fusion, 
mapped to the wings of the A domain on E2, a result that we recently confirmed by cryo-
electron microscopic analysis of CHK-152 Fab-virus particle complexes [45]. This 
epitope also was identified as a recognition site for neutralizing MAbs against VEEV 
[46] and SINV [47]. CHK-166, which was the least neutralizing (EC50 of ~100 ng/ml) of 
our highly protective MAbs mapped to an epitope in domain II of the E1 protein, adjacent 
to the highly conserved fusion loop. While anti-E1 MAbs against SINV and VEEV that 
protect or neutralize infection have been described [46,48,49], none have been 
characterized against CHIKV. A neutralizing human MAb (8B10) against CHIKV was 
reported with possible reactivity against E1, although further analysis revealed that it 
bound to the E1/E2 heterodimer [27,28]. CHK-102 and CHK-263 mapped to residues 
within the B domain on E2. A related epitope also was identified in mapping studies of 
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strongly neutralizing antibodies against Ross River virus [50], SINV [51,52], VEEV 
[46,53,54], and CHIKV [10,28]. The B domain on E2 comprises an important antigenic 
domain that is under selective pressure for antibody neutralization [41]. It serves as a cap 
to the fusion loop on E1 and because of its location at the tip of the heterodimeric spike 
[10,11] may contribute to attachment of cellular receptors.  
 In summary, we identified combinations of MAb pairs that were highly effective 
as post-exposure therapeutic agents. These findings are consistent with recent studies 
showing enhanced post-exposure efficacy of MAb combinations against Ebola [55], 
influenza A [56] and rabies [57] viruses. Our most promising pair of MAbs mapped to 
distinct epitopes, limited the generation of resistance, blocked multiple stages of the viral 
entry pathway, and protected Ifnar-/- mice against mortality even when administered 60 
hours after infection. CHK-152 was humanized as a first step towards a possible 
therapeutic for humans and demonstrated similar efficacy compared to the parent murine 
MAb. Tailored combinations of potently neutralizing MAbs show promise to prevent or 
treat infection by CHIKV, and likely other pathogenic alphaviruses in humans. 
Ultimately, a more detailed kinetic analysis of CHIKV infection in humans and 
determination of a treatment window relative to symptom onset is warranted to establish 
whether combination MAb therapy can prevent or mitigate acute or chronic and 
persistent infection and joint disease. 
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METHODS 
 Cells and viruses. Vero, Vero76 (ATCC), BHK21-15, and NIH 3T3 mouse 
fibroblast cells were cultured in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 5% or 15% (for 3T3 cells) fetal bovine serum (FBS) (Omega 
Scientific). C6/36 Aedes albopictus cells were grown in Leibovitz-15 medium 
supplemented with 10% FBS at 27oC. The infectious clones of CHIKV La Reunion 2006 
OPY-1 (strain 142, CHIKV-LR) and CHIKV-GFP (strain 145) were gifts from S. Higgs 
(Manhattan, KS) [58]. CHIKV-RSU1 and CHIKV-IbH35 were gifts of R. Tesh, 
(Galveston, TX). Infection studies of WT mice used the SL15649 strain of CHIKV, 
which was generated from an infectious clone [17]. The S27 African prototype CHIKV 
strain was a gift from Dr. S. Günther (Bernhard-Nocht-Institute for Tropical Medicine, 
Germany) and isolated from a patient in Tanzania in 1953.  
 Ethics statement. This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocols were approved by the Institutional Animal 
Care and Use Committee at the Washington University School of Medicine (Assurance 
Number: A3381-01) and the University of North Carolina (A3410-04). Dissections and 
footpad injections were performed under anesthesia that was induced and maintained 
with ketamine hydrochloride and xylazine, and all efforts were made to minimize 
suffering. 
 Generation of chimeric SFV-CHIKV. Chimeric SFV-CHIKV virus was 
generated by complementation of a double sub-genomic DNA-launched SFV replicon 
“backbone” plasmid (pSFV-GFP-BB) with the structural genes of CHIKV as described 
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recently for WNV [59]. The vectors and methods will be described in detail elsewhere 
(TY Lin, K. Dowd, and T. Pierson, in preparation). To generate SFV-CHIKV, a DNA 
fragment encoding WT or mutant CHIKV structural genes was ligated into the pSFV-
GFP-BB plasmid and transfected directly into HEK-293T cells using Lipofectamine 
LTX. The source of CHIKV structural genes was a sub-cloning vector pCHIKV-struct: 
mutations were introduced into this vector using site-directed mutagenesis and fully 
sequenced. Virus was harvested at 48, 72, or 96 hours after transfection, filtered, and 
stored at -80°C. 
 CHIKV protein. The CHIKV E2 ectodomain (residues S1-E361) and pE2-E1 
(E3-E2-E1: residues S1-R64 of E3, S1-E161 of E2, and Y1-Q411 of E1 including a 
(GGGS)4 polylinker between E2 and E1) of the CHIKV-LR strain were amplified from 
the infectious cDNA clone using high-fidelity Phusion PCR (Thermo Scientific). The E2 
ectodomain was cloned into pET21a, expressed in E. coli, and purified using an oxidative 
refolding protocol followed by size-exclusion column purification using fast protein 
liquid chromatography [60]. pE2-E1 was cloned into the mammalian expression vector 
pHLsec (Invitrogen) with a C-terminal octa-histidine tag and modified to express the 
Epstein–Barr virus EBNA-1 protein for enhanced protein expression. pE2-E1 was 
expressed in serum-free HEK-293F suspension cells and purified by Ni-NTA agarose 
affinity (Qiagen) and Superdex 200 gel filtration chromatography. 
 MAb generation. Irf7-/- mice were infected and boosted with 104 PFU of 
CHIKV-LR and, depending on the experiment, given a final intravenous (i.v.) boost with 
CHIKV virus-like particles [30], 25 µg of E2 protein, or 2 x 105 PFU of CHIKV-LR 
three days prior to fusion with myeloma cells. Hybridomas secreting antibodies that 
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reacted with CHIKV-GFP-infected BHK21-15 cells were identified by flow cytometry 
and cloned by limiting dilution. MAbs were isotyped by ELISA (Pierce), adapted for 
growth under serum-free conditions, and purified by protein G affinity and size exclusion 
chromatography. All MAbs were screened initially with a single endpoint neutralization 
assay using neat hybridoma supernatant (~10 µg/ml), which was incubated with 100 FFU 
of CHIKV-LR for one hour at 37oC. MAb-virus complexes were added to BHK21-15 cell 
monolayers in 6-well plates. After 90 minutes, cells were overlaid with 1% (w/v) agarose 
in Modified Eagle Media (MEM) supplemented with 4% FBS. Plates were fixed with 
10% formaldehyde in PBS 48 hours later, stained with crystal violet, and plaques were 
counted. The VH and VL sequence of neutralizing MAbs CHK-102, CHK-152, CHK-166, 
and CHK-263 were amplified from hybridoma cell RNA by a 5' RACE procedure Table 
S3 in Text S1).  
 Chimerization of MAbs. The generation of a chimeric mouse-human CHK-9 and 
CHK-152 with mouse VH and VL and human IgG1 constant regions was performed as 
described previously [60]. A point mutation that abolishes FcγR and C1q binding 
(N297Q) was introduced by QuikChange mutagenesis (Stratagene). Recombinant 
antibodies were produced after transfection of HEK-293T cells, harvesting of 
supernatant, and purification by protein A affinity chromatography. 
 Infection of mice. (a) Immunocompromised mice. Ifnar-/- mice were bred in 
pathogen-free animal facilities of the Washington University School of Medicine and 
infection experiments were performed in A-BSL3 facilities with the approval of the 
Washington University Animal Studies Committee. For prophylaxis studies, MAbs were 
administered by i.p. injection to 6 to 8 week-old Ifnar-/- mice one day prior to s.c. 
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infection in the footpad with 10 FFU of CHIKV-LR. For therapeutic studies, 10 FFU of 
CHIKV-LR was delivered 24, 48, 60, or 72 hours prior to administration of a single dose 
of individual or combinations of MAbs. To monitor viral burden in vivo, mice were 
treated with a single 100 g dose of anti-CHK or isotype control MAb one day before 
infection with 10 FFU of CHIKV-LR. Animals were sacrificed two days later for 
virological analysis. After extensive perfusion with PBS, organs were harvested, 
weighed, homogenized and virus was titered by focus-forming assay. (b) 
Immunocompetent mice. Four to six week-old C57BL/6 mice were infected s.c. in the 
footpad with 100 PFU of CHIKV SL15649 in 10 µl of PBS as described previously [17]. 
Some animals received 100 µg of MAb in 500 µl of PBS via an i.p. route before or after 
infection. Mice were monitored daily for footpad swelling. At 10 days after infection, 
mice were sacrificed and sections prepared from decalcified hind limbs [17] for 
histopathological analysis. All CHIKV studies with WT mice were performed under A-
BSL-3 conditions and in accordance with approved protocols following University of 
North Carolina guidelines. 
Neutralization assays. Serial dilutions of MAb were incubated with 100 FFU of 
CHIKV for one hour at 37oC. MAb-virus complexes were added to cells in 96-well 
plates. After 90 minutes, cells were overlaid with 1% (w/v) methylcellulose in Modified 
Eagle Media (MEM) supplemented with 4% FBS. Plates were harvested 18 to 24 hours 
later, and fixed with 1% PFA in PBS. The plates were incubated sequentially with 500 
ng/ml of ch-CHK-9 and horseradish peroxidase (HRP)-conjugated goat anti-human IgG 
in PBS supplemented with 0.1% saponin and 0.1% BSA. CHIKV-infected foci were 
visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot 
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5.0.37 macroanalyzer (Cellular Technologies Ltd). Non-linear regression analysis was 
performed, and EC50 values were calculated after comparison to wells infected with 
CHIKV in the absence of antibody. 
 Pre- and post-attachment neutralization assays. 96-well tissue culture plates 
were coated with 100 µl of poly-L lysine and seeded with 3 x 104 Vero cells/well 
overnight. For pre-attachment assays, dilutions of MAb were prepared at 4ºC in DMEM 
with 2% FBS and pre-incubated with 100 FFU of CHIKV-LR for one hour at 4ºC. MAb-
virus complexes were added to pre-chilled Vero cells for one hour at 4ºC. Non-adsorbed 
virus was removed with three washes of DMEM and adsorbed virus was allowed to 
internalize during a 37ºC incubation for 15 minutes. Cells were overlaid with 1% (w/v) 
methylcellulose in MEM supplemented with 4% FBS. The post-attachment assay was 
performed similarly, except that an equivalent amount of CHIKV was adsorbed first onto 
Vero cells for one hour at 4ºC. After removing free virus, dilutions of MAb were added 
to the virus-adsorbed cells for one hour at 4ºC. Virus was allowed to internalize and cells 
were overlaid with methylcellulose as described above. Nineteen hours later, the plates 
were harvested and analyzed for antigen-specific foci as described above.  
 Fusion inhibition assays. (a) Fusion from without assay. Virus fusion with the 
plasma membrane was assessed using a fusion from without (FFWO) assay [36]. Vero 
cells were seeded in 96-well plates, washed once with Binding medium (RPMI 1640, 
0.2% BSA, 10 mM HEPES pH 7.4, and 20 mM NH4Cl) at 4ºC, and incubated for 15 
minutes at 4ºC. CHIKV-LR (MOI of 15) was prepared in Binding medium and added to 
cells for one hour at 4ºC, and then free virus was removed. Subsequently, DMEM 
containing 2% FBS with or without CHIKV-specific or control MAbs (50 µg/ml) was 
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added to cells for one hour at 4ºC. FFWO was induced by the addition of pre-warmed 
fusion media (RPMI 1640, 0.2% BSA, 10 mM HEPES, and 30 mM succinic acid at pH 
5.5) for two minutes at 37ºC. In parallel wells, control media (RPMI 1640, 0.2% BSA, 10 
mM HEPES at pH 7.4) was added for 2 minutes at 37ºC to ensure that infection occurred 
only through pH-dependent plasma membrane fusion. Medium was removed and cells 
were incubated in DMEM supplemented with 5% FBS, 10 mM HEPES, and 20 mM 
NH4Cl (pH 7.4); NH4Cl prevented secondary infection through endosomal fusion 
pathways. Cells were detached 14 hours later, fixed with 1% PFA in PBS for 8 minutes, 
and permeabilized with 0.1% (w/v) saponin detergent solution. Cells were incubated 
sequentially with ch-CHK-9 and Alexa 647 conjugated goat anti-human IgG secondary 
antibody (Invitrogen). Infection was evaluated on a FACSArray flow cytometer (Becton-
Dickinson) and analyzed using FlowJo software. (b) Liposomal fusion assay. Pyrene-
labeled CHIKV (S27 African strain) was recovered from supernatants of infected Vero76 
cells cultured for 48 hours in the presence of 15 µg/ml 16-(1-pyrenyl)hexadecanoic acid 
(Invitrogen) as described [37]. Fusion of pyrene-labeled CHIKV with liposomes was 
monitored continuously in a Fluorolog 3-22 fluorometer (BFi Optilas), essentially as 
described [37]. Pyrene-labeled CHIKV and an excess of liposomes were mixed in a final 
volume of 665 µl in 5 mM HEPES, 150 mM NaCl, 0.1 mM EDTA, pH 7.4. Fusion was 
triggered by the addition of 35 µl 0.1 M MES, 0.2 M acetic acid, which achieved a pH of 
4.7. For the antibody inhibition experiments, pyrene-labeled CHIKV was incubated with 
increasing concentrations of CHIKV-152 or isotype control IgG2a MAb (MAb 0031, 
R&D systems) for 10 minutes at 37°C prior to mixing with liposomes. 
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 SPR. The binding of human FcγR and C1q to ch-CHK-152 and ch-CHK-152 
(N297Q) was analyzed by SPR using a BIAcore 3000 biosensor (GE Healthcare Life 
Sciences). MAbs were captured (~900 RU) after flowing over immobilized F(ab)’2 
fragments of goat anti-human F(ab)’2 specific IgG on a CM-5 sensor chip. Binding 
experiments were performed in HBS-EP buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 
mM EDTA, and 0.005% P20 surfactant). Binding of CD16A and CD64 (as monomeric 
soluble FcγR), CD32A (as dimeric soluble FcγR-aglycosylated Fc fusion), and C1q 
(Sigma-Aldrich) was analyzed at a single concentration. The FcγR and C1q were injected 
for 60 sec at a flow rate of 30 µl/min then allowed to dissociate over 2 minutes. Affinity 
measurements of CHK-152 MAbs for pE2-E1 were performed by SPR in HBS-EP 
buffer. Ch-CHK-152, ch-CHK-152 N297Q, hu-CHK-152 and mouse CHK-152 were 
captured (~300 RU) after flowing over immobilized F(ab)’2 fragments of goat anti-
human or anti-mouse Fc specific IgG. Purified pE2-E1 was injected at concentrations of 
0, 6.25, 12.5, 25, 50, and 100 nM, at a flow rate of 30 µl/min for 120 sec, and then 
allowed to dissociate over 2 minutes. Regeneration of capture surfaces was performed by 
pulse injection of 10mM glycine pH 1.5. Binding curve at the zero concentration of pE2-
E1 was subtracted from each experimental curve as a blank. Data were analyzed using 
BIAevaluation 4.1 software. Kinetic constants, ka and kd, were estimated by global fitting 
analysis of the association/dissociation curves to the 1:1 Langmuir interaction model. 
  Escape mutant selection. CHIKV-LR (1.2 x 105 FFU) was incubated with 25 
µg/ml of MAbs for one hour at 37ºC. Virus-MAb complexes were added to Vero cells 
and infection proceeded for 24 hours. At each passage, half of the supernatant was mixed 
(1:1) with 50 µg/ml of the selection MAb for one hour at 37ºC. These complexes were 
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added to a new monolayer of Vero cells for 2 hours, and the procedure was repeated from 
3 to 6 times depending on the selection MAb. Individual MAb-resistant viral plaques 
were picked and virus was grown in Vero cells in the presence of 10 µg/ml of MAb for 
24 hours. RNA was isolated from cells using an RNeasy kit (Qiagen) and cDNA was 
made with random hexamers using the Superscript III Reverse Transcriptase kit 
(Invitrogen) and amplified by PCR with primers flanking the structural genes (Table S4). 
The PCR product was sequenced using ten overlapping primer sets (Table S4). 
Mapping of mutations onto the CHIKV p62-E1 crystal structure. Figures 
were prepared using the atomic coordinates of CHIKV pE2-E1 (RCSB accession number 
3N44) using the program CCP4MG[61]. 
 Statistical analysis. For survival analysis, Kaplan-Meier survival curves were 
analyzed by the log-rank test. For growth kinetics and neutralization an unpaired T-test or 
analysis of variance was used to determine significance. These analyses were assessed 
using Prism software (GraphPad software). The protective effects of ch-CHK-152 versus 
ch-CHK-152 N297Q in wild type C57BL/6 mice were analyzed by the Kruskal-Wallace 
test with Bonferroni correction using the agricolae package of R (R Development Core 
Team, 2010. Foundation for Statistical Computing, Vienna, Austria).  
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FIGURE LEGENDS 
 Figure 1. Profile of neutralizing MAbs against CHIKV. A. Examples of MAb 
neutralization as judged by a reduction in the number of FFU using the Biospot 
Macroanalyzer. Rows 2 to 12 going across represent decreasing (3-fold) concentrations 
of CHK-152 or the negative control DENV1-E98 MAb. Column 1 shows infection in the 
absence of MAb. B. Increasing concentrations of CHK-95, CHK-102, CHK-166, CHK-
187, or CHK-263 were mixed with 100 to 150 FFU of CHIKV-LR for one hour at 37°C 
and Vero cells were infected. Neutralization was determined by FFU assay. C-D. CHK-
152 (C) or CHK-9 (D) was mixed with CHIKV-LR (East, Central and South African 
genotype), CHIKV-RSUI (Asian genotype), or CHIKV IbH35 (West African genotype) 
for one hour at 37°C and Vero or NIH 3T3 cells were infected as indicated. 
Neutralization was determined by FFU assay. Data in this Figure is pooled from three 
independent experiments performed in duplicate or triplicate. All error bars represent the 
standard deviations. 
 Figure 2. Efficacy of anti-CHIKV MAb prophylaxis. A. Six to eight week-old 
Ifnar-/- C57BL/6 mice were passively transferred 100 µg of the indicated MAbs via an 
i.p. injection one day before infection with 10 FFU of CHIKV-LR via a s.c. route. The 
percentage and number of surviving mice were as follows: DENV1-E98 (0%, 0 of 9), 
CHK-88 (62.5%; 5 of 8), CHK-95 (12.5%; 1 of 8), CHK-98 (28.6%; 2 of 7), CHK-102 
(100%; 8 of 8), CHK-124 (75%; 6 of 8), CHK-151 (87.5%; 7 of 8), CHK-152 (100%; 8 
of 8), CHK-155 (85.7%; 6 of 7), CHK-165 (28.6%; 2 of 7), CHK-166 (100%; 8 of 8), 
CHK-175 (75%; 6 of 8), CHK-187 (50%; 4 of 8), CHK-263 (100%; 8 of 8), or CHK-266 
(0%; 0 of 8). MAbs italicized in red in the Figure provided 100% protection. B. Ifnar-/- 
mice were passively transferred 10 µg of MAb via an i.p. injection one day before 
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infection with 10 FFU of CHIKV-LR via a s.c. route. The percentage and number of 
surviving mice were as follows: DENV1-E98 (0%; 0 of 7), CHK-102 (12.5%; 1 of 8), 
CHK-152 (83%; 10 of 12), CHK-166 (0%; 0 of 12), or CHK-263 (73%; 8 of 11). For (A) 
and (B) the survival curves were constructed from data of at least two independent 
experiments. All anti-CHK MAbs provided statistically significant protection in the 
percentage of surviving animals or mean survival time compared to the control DENV1-
E98 MAb (P < 0.05). C-G. Viral burden in MAb-treated Ifnar-/- mice. Animals were 
passively transferred 100 µg of the indicated MAbs (CHK-102, CHK-152, CHK-166, 
CHK-263, or isotype control DENV1-E98) via an i.p. injection one day before infection 
with 10 FFU of CHIKV-LR via a s.c. route. Two days later, viremia (C) and tissues (D, 
spleen; E, liver; F, muscle; and G, brain) were harvested and infectious virus was titrated 
by focus-forming assay. Results are pooled from two independent experiments (n = 4 
mice per group). The dashed line indicates the limit of detection of the assay and the solid 
bar indicates the median values. All viral burden results with CHK-102, CHK-152, CHK-
166, and CHK-263 were statistically different (P < 0.02) from those obtained with 
DENV1-E98, as analyzed by the Mann-Whitney test. H. Four week-old female WT 
C57BL/6 mice were sham-treated or administered 100 µg of CHK-102 or CHK-152 via 
an i.p. route. 24 hours later, mice were infected with 100 PFU of CHIKV-SL 15649 and 
at day 10, virus-induced pathology in the foot and ankle joint was assessed. (Outer left) 
Sham-infected, (middle left) CHIKV infected and sham-treated, (middle right) CHIKV-
infected and CHK-102 treated, and (outer right) CHIKV infected and CHK-152 treated. 
Shown are representative images after hematoxylin and eosin staining from at least 3 
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mice per group at 100x magnification. Yellow and green arrows indicate regions of 
inflammation or normal joints, respectively. 
Figure 3. Mechanism of neutralization by CHIKV MAbs. A. Pre- and post-
attachment inhibition assays. Vero cells were pre-chilled to 4ºC and 100 FFU of CHIKV-
LR was added to each well for one hour. After extensive washing at 4oC, the indicated 
MAbs were added for one hour at 4ºC, and then the FRNT protocol was completed (black 
lines, Post). In comparison, a standard pre-incubation FRNT with all steps performed at 
4ºC is shown for reference. Virus and MAb are incubated together for one hour at 4oC, 
prior to addition to cells (red lines, Pre). Data shown are representative of three 
experiments performed in duplicate with error bars representing standard deviation. B-C. 
FFWO assay. CHIKV was incubated with Vero cells at 4oC to allow virus attachment. 
Free virus was removed after washing and 50 µg/ml of the indicated MAbs (including 
DENV1-E98, a negative control MAb) were added at 4oC. Viral fusion at the plasma 
membrane was induced after a brief exposure to a low pH buffer. After pH normalization, 
cells were cultured for 14 hours in the presence of NH4Cl to inhibit infection through the 
endosomal pathway. Cells were analyzed for infection by staining with an anti-E2 MAb. 
Representative histograms are shown (B) and the data was pooled from four independent 
experiments for statistical analysis (C). For simplicity of display, not all of the MAbs 
included in the summary graph are shown by flow cytometry analysis. Asterisks indicate 
values that are statistically different (P < 0.05) from the control MAb. Error bars 
represent standard deviations. Note low pH-triggered viral fusion at the plasma 
membrane is an inefficient process with only 10 to 20% of cells becoming infected even 
when a high MOI was used. D-E. Viral membrane fusion with liposomes. Fusion of 
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pyrene-labeled CHIKV was measured at pH 4.7 (37°C) using liposomes consisting of 
phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, and cholesterol in a 
molar ratio of (1/1/1/1.5), as described in the Methods. (D) Curve a, no MAb; curve b, 
0.1 nM CHK-152; curve c, 1 nM CHK-152; curve d, 10 nM CHK-152. (E) Extent of 
fusion (average value between 50 to 60 seconds post acidification) at increasing 
concentrations of MAb. Black bars, CHK-152; white bar, isotype control (MAb 0031, 
only included at 10 nM concentration). All fusion measurements were performed at least 
three independent times.   
Figure 4. The effector functions of CHK-152 contribute to protection in vivo. 
A. Comparison of binding of ch-CHK-152 and agylocsyl ch-CHK-152 N297Q to pE2-
E1, as measured by surface plasmon resonance. A single representative sensogram is 
shown for each MAb. The experimental curves (colored lines) were fit using a 1:1 
Langmuir analysis (dashed lines), after double referencing, to determine the kinetic 
parameters presented in the Table immediately below. B. Comparison of neutralizing 
activity of murine CHK-152, ch-CHK-152, and ch-CHK-152 N297Q, as measured by 
FRNT on Vero cells. C. Comparison of binding of ch-CHK-152 and ch-CHK-152 
N297Q to FcγR (CD16A, 500 nM; CD32A, 100 nM; and CD64, 100 nM) or C1q (50 
nM), as measured by surface plasmon resonance. D. Comparison of pre-exposure 
protective activity of ch-CHK-152 and ch-CHK-152 N297Q. Ifnar-/- mice were 
administered via an i.p. injection 10 µg of ch-CHK-152 and ch-CHK-152 N297Q one day 
before infection with 10 FFU of CHIKV-LR via a s.c. route. Mice were monitored for 
survival for 21 days after infection. The survival curves were constructed from data of at 
least two independent experiments and the number of animals for each antibody ranged 
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from 8 to 10 per group. ch-CHK-152 provided statistically greater protection than ch-
CHK-152 N297Q (P < 0.05). E. Five week-old WT C57BL/6 mice were infected with 
100 PFU of CHIKV in the left rear footpad and either sham-treated, or treated with 100, 
50, or 25 µg of ch-CHK-152 (left panel) or ch-CHK-152 N297Q (right panel) at 18 hours 
post infection. Mice were scored daily for virus-induced footpad swelling, where a score 
of 0 = no swelling, 1 = mild swelling where the top of the foot is slightly raised, 2 = 
moderate swelling with the entire top of foot raised, and 3 = severe swelling involving 
both the top and bottom of the foot. Scores are the mean values for 7 to 8 mice per 
treatment group and are representative of three independent experiments. Ch-CHK-152 
mediated protection was significantly greater than ch-CHK-152 N297Q on days 7, 8, and 
9 post infection for the 100 µg antibody dose, and at day 7 post infection for the 50 µg 
dose, as determined by the Kruskal-Wallace test with Bonferroni correction (P < 0.05). 
No statistically significant differences between ch-CHK-152 and ch-CHK-152 N297Q 
were observed with the 25 µg dose. Of note, we observed a reproducible decrease in 
clinical score on day 5 in many animals. This reflects the biphasic pattern of swelling: 
during the first 3 to 4 days, swelling is due to edema, whereas after day 5, it is due to 
inflammatory cell infiltration into the foot and ankle. 
 Figure 5. Therapeutic efficacy of anti-CHIKV MAbs. A. Ifnar-/- mice were 
passively transferred via an i.p. injection 100 µg of DENV1-E98, CHK-102, CHK-152, 
CHK-166, or CHK-263 or 50 µg each of CHK-102 + CHK-152, CHK-166 + CHK-152, 
CHK-263 + CHK-152, or CHK-102 + CHK-263 at 24 hours after CHIKV infection. B. 
Five week-old WT C57BL/6 mice were infected with 100 PFU of CHIKV in the footpad 
and either sham-treated, or treated with 100 or 50 µg of CHK-152 at 18 hours post 
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infection. Virus induced pathology in the foot and ankle joint was assessed by 
histopathological analysis at day 10 post-infection. (Left) CHIKV-infected, sham-treated, 
(middle) CHIKV-infected, CHK-152 (100 µg) treated at + 18 hours, and (right) CHIKV-
infected, CHK-152 (50 µg) treated at + 18 hours. Shown are representative images after 
hematoxylin and eosin staining from 3 mice per group at 100x magnification. Yellow and 
green arrows indicate regions of inflammation or normal joints, respectively. C. Ifnar-/- 
mice were passively transferred via an i.p. injection 200 µg of DENV1-E98 or 100 µg 
each of CHK-102 + CHK-152, CHK-166 + CHK-152, or CHK-263 + CHK-152 at 48 
hours after CHIKV infection. D. Ifnar-/- mice were passively transferred via an i.p. 
injection 500 µg of DENV1-E98 or 250 µg each of CHK-102 + CHK-152 or CHK-166 + 
CHK-152 at 60 hours after CHIKV infection. For A, C, and D the survival curves were 
constructed from data of at least two independent experiments. The number of animals 
for each antibody ranged from 8 to 10 per group, with the exception of CHK-102 + CHK-
263, which was performed with 7 mice only. Statistically significant differences in 
protection compared to DENV1-E98 are described in the text. 
Figure 6. Characterization and mapping of neutralization escape mutants. A-
D. FRNT assay with bulk virus obtained after three to six passages under selection of (A) 
CHK-102, (B) CHK-152, (C) CHK-166, or (D) CHK-263 on Vero cells. Bulk virus also 
was tested for infectivity in the presence of the non-selecting MAbs. Results are 
representative of two to three independent experiments performed in triplicate. E-H. 
Confirmation of resistant phenotype with SFV-CHIKV-GFP containing the indicated 
single engineered point mutations. Serial dilutions of MAb were incubated with chimeric 
SFV-CHIKV virus (WT or mutant stocks) for one hour at room temperature. MAb-virus 
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complexes were added to Vero cells plated in 96-well plates and incubated at 37°C. After 
8 hours cells were trypsinized, fixed, and the number of GFP-positive, infected cells was 
assessed by flow cytometry. Curves are representative of 2 to 3 independent experiments. 
I. Epitope mapping of anti-CHIKV MAbs on the crystal structure of the mature envelope 
glycoprotein complex (PDB code 3N44). (Left) The domains on E2 (cyan) and E1 (gold) 
are indicated, and the fusion loop on E1 (E1 FL) is delineated. Amino acid residues of 
neutralizing MAbs were determined by escape selection, sequencing, and reverse genetic 
confirmation. CHK-102 and CHK-263 recognize the B domain on E2, CHK-152 
recognizes a residue on the wings of the A domain on E2, and CHK-166 recognizes an 
amino acid in domain II of E1 proximal to the conserved fusion loop. (Right) The mature 
envelope glycoprotein docked onto the trimer conformation (PDB code 2XFB) that is 
present on the virion. E3, E2, and E1 and the escape residues are colored as in the left 
panel. Neutralization escape residues are readily accessible on the top of the trimer, distal 
to the viral membrane. 
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Table 1. Inhibitory activity of neutralizing anti-CHIKV MAbs 
MAb CHIKV-
LR 
EC50 
ng/ml 
(CI) 
Vero 
CHIKV-
LR 
EC90 
ng/ml 
(CI) 
Vero 
CHIKV-
LR 
EC50 
ng/ml 
(CI) 
3T3 
CHIKV-
RSU1 
EC50 
ng/ml 
(CI) 
Vero 
CHIKV-
RSU1 
EC90 
ng/ml 
(CI) 
Vero 
CHIKV-
IbH35 
EC50 
ng/ml 
(CI) 
Vero 
CHIKV-
IbH35 
EC90 
ng/ml 
(CI) 
Vero 
CHK-9 
36 (31-
43) 
882 (612-
1271) 
37 (27-51) 
3712 
(2636 - 
5229) 
>10,000 68 (54-87) 
1478 (885-
2469) 
CHK-11 1356 
(1049-
1753) 
>10,000 
4680 
(3691-
5932) 
215 (150-
308) 
>10,000 
1141 (570-
2284) 
>10,000 
CHK-48 16 (14-
20) 
430 (304-
607) 
32 (17-61) 8 (7-11) 
220 (121-
399) 
7 (5-9) 
359 (193-
669) 
CHK-65 
7 (6-9) 
587 (330-
1047) 
25 (15-43) 5 (4-6) 
265 (164-
431) 
4 (3-5) 
147 (80-
271) 
CHK-77 48 (41-
56) 
576 
(407-817) 
91 (53-
155) 
17 (14-20) 
368 (250-
543) 
27 (22-32) 
444 (291-
677) 
CHK-88 
5 (3-6) 
422 (230-
776) 
12 (7-21) 2 (2-3) 
190 (106-
343) 
2 (2-3) 
211 (104-
431) 
CHK-95 
4 (3-5) 
156 (90-
271) 
6 (4-10) 6 (5-8) 
411 (246-
686) 
2 (1-3) 
176 (76-
404) 
CHK-96 
40 (33-
50) 
8457 
(5115-
13982) 
>10,000 
95 (65 -
139) 
>10,000 19 (14-26) 
4486 
(2126-
9466) 
CHK-98 
155 (130-
183) 
5337 
(3630-
7846) 
394 (220-
706) 
21 (16- 
27) 
2022 
(950-
4304) 
103 (80-
131) 
7923 
(4494-
13968) 
CHK-102 
14 (11-
17) 
351 (227-
543) 
30 (17-53) 5 (4-7) 
1318 
(532-
3261) 
6 (5-7) 
104 (68-
161) 
CHK-105 
19 (16-
23) 
1156 
(773-
1728) 
94 (59-
150) 
11 (9-14) 
927 (563-
1528) 
11 (9-13) 
645 (433-
960) 
CHK-112 
11 (9-13) 
235 (162-
339) 
12 (8-19) 8 (6-11) 
2116 
(1072-
4174) 
4 (3-5) 
115 (76-
176) 
CHK-124 4 (4-6) 101 (66- 10 (5-22) 3 (2-4) 228 (129- 3 (2-3) 96 (55-167) 
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156) 402) 
CHK-140 
9 (8-11) 
219 (137-
348) 
56 (32-98) 8 (6-11) 
721 (345-
1508) 
5 (4-6) 83 (55-125) 
CHK-142 
9 (7-11) 
369 (238-
572) 
32 (21-48) 7 (5-10) 
731 (321-
1668) 
4 (3-5) 
108 (66-
177) 
CHK-143 
34 (23-
51) 
>10,000 
277 (76-
1010) 
6 (5-9) 
3456 
(1332-
8965) 
12 (7-23) 
3094 (728-
13143) 
CHK-151 6883 
(3467-
13665) 
>10,000 >10,000 
261(154-
440) 
>10,000 
5784 
(2785-
12015) 
>10,000 
CHK-152 2 (2-2) 10 (9-12) 1 (1-2) 3 (2-3) 15 (11-22) 1 (1-2) 6 (5-8) 
CHK-155 
5 (5-7) 
110 (73-
166) 
7 (6-8) 4 (4-5) 
93 (61-
142) 
2 (2-3) 52 (32-86) 
CHK-164 3523 
(2904-
4274) 
>10,000 
4395 
(3045-
6342) 
1637 
(1182-
2265) 
>10,000 
2366 
(1582-
3538) 
>10,000 
CHK-165 9725 
(6275-
15070) 
>10,000 >10,000 
1817 
(111-
2972) 
>10,000 >10,000 >10,000 
CHK-166 
154 (116-
205) 
8604 
(4459-
16604) 
202 (98-
418) 
40 (30-52) 
2175 
(1195-
3959) 
82 (59-114) 
2576 
(1234-
5379) 
CHK-175 
6 (5-8) 
423 (285-
626) 
5 (3-10) 3 (3-4) 
343 (199-
593) 
4 (3-5) 
662 (295-
1489) 
CHK-176 806 (616 
- 1055) 
>10,000 >10,000 >10,000 >10,000 >10,000 >10,000 
CHK-180 
140 (104 
-186) 
7615 
(3907-
14843) 
168 (74-
384) 
49 (38-63) 
2588 
(1465-
4570) 
79 (58-108) 
1597 (802-
3180) 
CHK-187 
11 (9-12) 
524 (355-
772) 
17 (8-34) 7 (6-8) 
140 (97-
203) 
5 (4-7) 
186 (91-
383) 
CHK-189 4325 
(3172-
5897) 
>10,000 
3974 
(2119-
7451) 
951 (589-
1538) 
>10,000 
3809 
(1856-
7816) 
>10,000 
CHK-262 4934 
(3938-
6181) 
>10,000 
3740 
(2488-
5623) 
4622 
(3376-
6328) 
>10,000 
3306 
(2049-
5336) 
>10,000 
CHK-263 
5 (5-7) 
136 (93-
197) 
2 (2-4) 4 (3-5) 48 (32-73) 2 (2-2) 51 (36-74) 
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CHK-264 
18 (13-
23) 
>10,000 6 (4-10) 9 (7-14) 
1019 
(430-
2419) 
11 (7-16) 
5962 
(2099-
16932) 
CHK-265 
8 (7-9) 
207 (148-
289) 
6 (4-8) 5 (4-6) 
143 (88-
234) 
5 (4-6) 
201 (103-
389) 
CHK-266 2187 
(1642-
2913) 
>10,000 
1500 
(1093-
2059) 
>10,000 >10,000 
1330 (814-
2173) 
>10,000 
CHK-267 
18 (14-
23) 
1063 
(628-
1799) 
3 (3-5) 9 (7-11) 
452 (262-
780) 
14 (6-34) 
3694 (468-
29151) 
CHK-268 
24 (19-
30) 
934 (567-
1540) 
10 (7-14) 22 (17-29) 
1212 
(641-
2289) 
10 (8-13) 
468 (278-
789) 
CHK-269 
136 (104-
178) 
>10,000 32 (18-57) 50 (33-76) >10,000 47 (33-69) 
3834 
(1617-
9090) 
CHK-270 
14 (10-
21) 
9302 
(3777-
22912) 
N.D. 14 (10-18) 
669 (340-
1317) 
8 (6-11) 
748 (363-
1537) 
 
Neutralizing activity was determined by FRNT on Vero or NIH 3T3 cells with increasing 
concentrations of purified MAbs and 100 FFU of the indicated CHIKV strains 
corresponding to different genotypes (CHIKV-LR, East, Central, and South African; 
CHIKV-RSUI, Asian and, IbH35, West African). The data were derived from three 
independent experiments performed in duplicate or triplicate. The inhibitory 
concentrations of MAb that reduced infected foci by 50% (EC50) and 90% (EC90) were 
calculated by nonlinear regression analysis and are expressed as ng/ml of antibody. In 
parenthesis, immediately below the EC50 and EC90 values, are confidence intervals (CI). 
Bold red indicates that the EC50 or EC90 value was greater than the highest 
concentration (10,000 ng/ml) of MAb used. Bold blue indicates an EC50 or EC90 value 
of less than 10 ng/ml, which reflects a highly neutralizing MAb for a given cell type or 
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virus strain. N.D. indicates not determined. Of note, NIH 3T3 cells are less permissive 
than Vero cells (1 FFU on NIH 3T3 cells = 35 FFU on Vero cells). 
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Table 2. In vitro selection of viruses resistant to MAb neutralization 
MAb Mutationa # of plaque picks 
CHK-102 E2: L210P 6 of 8 
CHK-102 E2: G209E 2 of 8 
CHK-152 E2: D59N 9 of 9 
CHK-152 E2: A89Eb 2 of 9 
CHK-166 E1: K61T 14 of 14 
CHK-263 E2: K215E 3 of 4 
CHK-263 E2: G209E 1 of 4 
 
aIn vitro selection for neutralization escape variants was performed by passaging 
CHIKV-LR in the presence of 25 µg/ml of the indicated MAbs. Resistant virus was 
isolated at passage 3 (CHK-102, CHK-152, and CHK-263) or passage 6 (CHK-166), 
plaque purified, and sequenced. 
bThe A89E mutant was identified after sequencing of CHK-152 escape mutants in cell 
culture, but was determined to be insignificant for CHK-152 neutralization by reverse 
genetic analysis (see Fig 6F). 
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Table 3. In vivo selection of viruses resistant to MAb neutralization 
MAb Condition 
EC50 (ng/ml) 
(Parentmutant) 
Mutationa 
CHK-102 - 24 h, 10 µg 11 >10,000 E2: L210P 
CHK-102 + 24 h, 100 µg 11 >10,000 E2: G209E 
CHK-152 -24 h, 10 µg 2 10,000 
E2: N231D 
E2: K233E 
CHK-152 -24 h, 10 µg 2 3,000 E2: K233E 
CHK-152 + 24 h, 100 µg 2 >10,000 E2: D59N 
CHK-152 + 24 h, 100 µg 2 >10,000 E2: K233T 
CHK-166 + 24 h, 100 µg 170>10,000 E1: G64S 
CHK-263 + 24 h, 100 µg 5 >10,000 E2: G209E 
CHK-166 + 
CHK-152 
+48 h, 250 µg 
CHK-166: 170 540 
CHK-152: 2 2.6 
E2: N332I 
 
aIn vivo selection for resistant virus was performed by administering the indicated 
individual or combinations of MAbs before (-24 hours) or after (+ 24 or 48 hours) 
CHIKV-LR infection. Resistant virus was isolated directly from tissues (leg and brain), 
and cDNA was prepared by reverse transcription and sequenced. The change in 
neutralizing activity of the bulk virus recovered from tissue is highlighted by the 
differences in EC50 values. 
 
 
 
 
69 
 
70 
 
71 
 
72 
 
73 
 
74 
 
 
75 
 
SUPPORTING INFORMATION 
Figure S1. Screening of hybridoma supernatants for binding to CHIKV-infected 
cells.  
 Figure S2. Binding kinetics of CHK-MAbs to pE2-E1. 
 Figure S3. Pre- and post-attachment neutralization assays. 
Figure S4. Construction and efficacy of humanized CHK-152.  
 Figure S5. Interaction of neutralizing MAbs.  
 Figure S6. Selection of escape E1-G64S escape mutant in vivo against CHK-   166. 
 Figure S7. Confirmation of neutralization escape mutants selected in vivo.  
 Figure S8. Relative resistance of CHIKV recovered from mice after treatment with 
combination MAb therapy. 
 Table S1. List of anti-CHIKV MAbs. 
 Table S2. Cross-neutralization of infection by wild type and mutant SFV-CHIKV 
infection with anti-CHIKV MAbs. 
 Table S3. List of VH and VL sequences of CHK-102, CHK-152, CHK-166, and CHK-
263 mouse MAbs. 
 Table S4. Primers used for sequencing and amplifying the structural genes of 
CHIKV-LR 2006-OPY1. 
 Text S1. Supplemental Methods. 
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SUPPORTING INFORMATION 
 Figure S1. Screening of hybridoma supernatants for binding to CHIKV-
infected cells. Hybridoma supernatants were incubated with CHIKV-GFP infected 
BHK21 cells and tested for immunoreactivity by flow cytometry. Shown are examples of 
a negative control MAb (DENV3-E2), three ‘hits’ (later named as CHK-102, CHK-117, 
and CHK-130), and a negative supernatant (5E3). The y-axis shows GFP staining 
associated with the reporter gene that is translated from the subgenomic promoter of 
CHIKV, and the x-axis shows staining of the tested mouse MAb. Double-positive cells 
were considered ‘hits’ in the screen. The result is representative of many different MAbs 
performed in the original screen. 
 Figure S2. Binding kinetics of CHK-MAbs to pE2-E1. Binding curves and 
kinetic parameters of pE2-E1 binding to mouse CHK-102, CHK-152, CHK-166, and 
CHK-263 MAbs. A single representative sensogram is shown for each MAb. The 
experimental curves (colored lines) were fit using a 1:1 Langmuir analysis (dashed lines), 
after double referencing, to determine the kinetic parameters presented immediately 
below.  
 Figure S3. Pre- and post-attachment neutralization assays. Vero cells were 
pre-chilled to 4ºC and 100 FFU of CHIKV-LR was added to each well for one hour at 4 
ºC. After extensive washing at 4oC, the indicated MAbs (CHK-48, CHK-65, CHK-95, 
CHK-112, CHK-124, CHK-142, CHK-155, CHK-175, CHK-84 and DENV1-E98) were 
added for one hour at 4ºC, and then the FRNT protocol was completed (black lines, 
Post). In comparison, a standard pre-incubation FRNT with all steps performed at 4ºC is 
shown for reference. Virus and MAb are incubated together for one hour at 4oC, prior to 
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addition to cells (red lines, Pre). Data shown are representative of three experiments 
performed in duplicate with error bars representing standard deviation. 
Figure S4. Construction and efficacy of humanized CHK-152. We amplified 
the cDNA encoding the heavy (VH) and light (VL) variable domains from the hybridoma 
cellular RNA and grafted the complementarity determining regions onto the human VH1-
18 and human Vκ-L6 backbones. The resulting humanized VH and VL were combined 
with human γ1 and κ constant regions, fused to an IgG signal sequence, expressed in 
293T cells and purified (data not shown). A. Binding curves and kinetic parameters of 
pE2-E1 binding to mouse CHK-152 and hu-CHK-152. A single representative sensogram 
is shown for each MAb. The experimental curves (colored lines) were fit using a 1:1 
Langmuir analysis (dashed lines), after double referencing, to determine the kinetic 
parameters presented in the Table immediately below. B. Neutralization studies with 
mouse CHK-152 and hu-CHK-152. Neutralizing activity was determined by FRNT assay 
on Vero cells. Samples were performed in duplicate and the experiment is one 
representative of three. C. Pre-exposure protective activity of hu-CHK-152. Ifnar-/- mice 
were passively transferred via an i.p. injection 10 or 100 µg of mouse hu-CHK-152 one 
day before CHIKV infection. Mice were monitored for survival for 21 days after 
infection. The survival curves were constructed from data of at least two independent 
experiments and the number of animals for each antibody ranged from 8 to 10 per group.  
 Figure S5. Interaction of neutralizing MAbs. A. Virion capture ELISA and 
competition of MAb binding. 96-well plates were coated with 5 µg/ml of CHK-65 MAb. 
Plates were washed, blocked and 3 x 106 FFU of CHIKV 181-25 was captured. 
Subsequently, plates were incubated with the indicated anti-CHK mouse MAbs (CHK-
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102, CHK-152, CHK-166, or CHK-263) or controls (no MAb, PBS; irrelevant MAb, 
WNV E28) for one hour. After washing, plates were incubated sequentially with 125 
ng/ml hu-CHK-152 and biotin-labeled goat anti-human secondary antibody. After 
washing and incubation with HRP-conjugated streptavidin, plates were developed and 
emission (450 nm) was read using an iMark microplate reader (Bio-Rad). Results are 
representative of three independent experiments, each performed in triplicate. B. 
Neutralizing activity of MAb combinations. Increasing concentrations of individual 
MAbs (CHK-102, CHK-152, CHK-166, and CHK-263) or combinations of MAbs (CHK-
102 + CHK-152, CHK 102 + CHK-263, CHK-152 + CHK-166, or CHK-152 + CHK-
263) were mixed with 100 FFU of CHIKV-LR for one 1 hour at 37°C and Vero cells 
were infected. Neutralization was determined by FFU assay. Data is representative of 
three independent experiments performed in duplicate.  
 Figure S6. Selection of escape E1-G64S escape mutant in vivo against CHK-
166. Ifnar-/- mice were infected with CHIKV and 24 hours later given a single 100 µg 
dose of CHK-166 therapy. Virus was recovered from the contralateral leg and brain from 
one moribund mice and the structural genes were sequenced. All 2 of 2 viral isolates 
recovered showed a single point G64S mutation in the E1 gene. This isolate was tested 
subsequently for neutralization by CHK-102 (EC50 of 161 ng/ml), CHK-152 (EC50 of 2 
ng/ml), CHK-166 (EC50 > 10,000 ng/ml) and CHK-263 (25 ng/ml).  Data is the average 
of two independent experiments performed in triplicate. 
 Figure S7. Confirmation of neutralization escape mutants selected in vivo. 
Confirmation of resistant phenotype selected with CHK-152 in vivo using SFV-CHIKV-
GFP containing the indicated single engineered point mutations. Serial dilutions of CHK-
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152, CHK-102, and CHK-263 were incubated with chimeric SFV-CHIKV virus (WT or 
mutant stocks) for one hour at room temperature. MAb-virus complexes were added to 
Vero cells plated in 96-well plates and incubated at 37°C. After 8 hours cells were 
trypsinized, fixed, and the number of GFP-positive, infected cells was assessed by flow 
cytometry. Curves are representative of 2 independent experiments.  
 Figure S8. Relative resistance of CHIKV recovered from mice after 
treatment with combination MAb therapy. Ifnar-/- mice were infected with CHIKV 
and 48 hours later given a single dose of combination MAb (CHK-102 + CHK-152 or 
CHK-166 + CHK-152) therapy. Virus was recovered from the contralateral leg and/or 
brain from the few moribund mice and the structural genes were sequenced. Two viral 
isolates showed differences in neutralization patterns that corresponded to amino acid 
substitutions (see Table 2). Neutralization analysis of these viruses recovered from 
animals treated with (left) CHK-102 and CHK-152 or (right) CHK-166 and CHK-152 
and tested against the respective MAbs. A comparison with the parent virus is shown. 
The curves are representative of two independent experiments performed in triplicate, 
and error bars indicate standard deviations. 
 Table S1. List of anti-CHIKV MAbs. All MAbs listed were cloned successfully 
by limiting dilution. Isotypes were assigned based on a commercial assay. MAbs CHK-1 
to CHK-51 were produced from mice receiving a final boost with CHIKV VLP; MAbs 
CHK-52 to CHK-145 were produced from mice receiving a final boost with recombinant 
E2 protein; and MAbs CHK-146 to CHK-270 were produced from mice receiving a final 
boost with either recombinant E2 protein or infectious CHIKV-LR. Binding to soluble E2 
or pE2-E1 expressed in bacteria or mammalian cells was determined by ELISA. N.D. 
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indicates not determined. Yes, reflects binding that yielded an O.D. value of > 1.1; Weak, 
indicates binding with an O.D. value of > 0.8 and < 1.1; Background binding (irrelevant 
MAb control) had an O.D. value of 0.2. 
 Table S2. Cross-neutralization of infection by wild type and mutant SFV-
CHIKV infection with anti-CHIKV MAbs. CHIKV escape variants were selected in 
the presence of the indicated neutralizing MAbs. After sequencing of escape variants, the 
indicated amino acid substitutions were engineered into an infectious SFV-GFP-CHIKV 
chimeric virus for analysis of resistance or sensitivity to neutralization. Viruses denoted 
as “resistant” were not neutralized appreciably by the indicated MAbs, whereas viruses 
marked “sensitive” showed no greater than a 2-fold difference in EC50 values compared 
to the parent virus. Results are from two to four independent dose-response experiments 
performed in duplicate with nine serial dilutions of each MAb.  
 Table S3. List of VH and VL nucleotide and corresponding amino acid sequences 
of CHK-102, CHK-152, CHK-166, and CHK-263 mouse MAbs. 
 Table S4. Primers used for sequencing and amplifying the structural genes of 
CHIKV-LR 2006-OPY1. 
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SUPPLEMENTAL METHODS 
 Humanization of CHK-152. To construct a humanized version of CHK-152, a 
cDNA encoding the CDR from the VH and VL variable domains were amplified from 
hybridoma cell RNA by a 5' RACE procedure and grafted onto the homologous human 
VH (1-18) and Vκ (L-6) backbones. The resulting humanized VH and VL were combined 
with human γ1 and κ constant regions, fused to an IgG signal sequence and inserted into 
a pCI-neo cassette to construct the heavy and light chain expression plasmids. 
Competition ELISA Polystyrene 96-well plates were coated overnight at 4°C 
with 5 µg/ml of CHK-65 MAb in sodium carbonate buffer (pH 9.3). Plates were washed 
three times in PBS with 0.02% Tween 20 and blocked for one hour at 37°C with PBS, 
2% BSA, and 0.02% Tween 20. 3 X 106 FFU of CHIKV 181-25 (gift of R. Tesh, 
Galveston, TX) was captured, and plates were washed four times with PBS with 1% BSA 
and incubated with murine MAbs for one hour. After washing, plates were incubated 
with 125 ng/ml hu-CHK-152 in PBS with 1% BSA. Plates were washed and biotin-
labeled goat anti-human secondary antibody (Jackson Labs) was added for one hour. 
After washing and incubation with HRP-conjugated streptavidin (Vector Laboratories), 
plates were developed with tetramethylbenzidine substrate (Dako). The reaction was 
stopped with the addition of 2 N H2SO4, and emission (450 nm) was read using an iMark 
microplate reader (Bio-Rad). 
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Table S1. List of anti-CHIKV MAbs. 
MAba Isotype E2b MAb Isotype E2 MAb Isotype E2 MAb Isotype E2 
CHK-
1 
IgG2c No 
CHK-
59 
IgG2c Yes CHK-
127 
IgG1 Yes CHK-
206 
IgG1 No 
CHK-
2 
IgG2c No 
CHK-
60 
IgG2c Yes CHK-
129 
IgG2c Yes CHK-
207 
N.D. N.D. 
CHK-
3 
IgG2c weak 
CHK-
61 
IgG2c Yes CHK-
130 
IgG2b Yes CHK-
208 
IgM No 
CHK-
4 
IgG2c Yes 
CHK-
62 
IgG2c Yes CHK-
131 
IgG2c Yes CHK-
209 
N.D. N.D. 
CHK-
5 
IgG2b Yes 
CHK-
63 
IgG2b Yes CHK-
133 
IgG2b/c Yes CHK-
210 
N.D. N.D. 
CHK-
6 
IgG2c Yes 
CHK-
64 
IgG2c Yes CHK-
134 
IgG1 Yes CHK-
211 
N.D. N.D. 
CHK-
7 
IgG3 weak 
CHK-
65 
IgG2c Yes CHK-
135 
IgG2c Yes CHK-
212 
N.D. N.D. 
CHK-
8 
IgG2c No 
CHK-
66 
IgG2c Yes CHK-
138 
IgG2c Yes CHK-
213 
IgG2c No 
CHK-
9 
IgG2c Yes 
CHK-
67 
IgG2c Yes CHK-
140 
IgG2c Yes CHK-
214 
N.D. N.D. 
CHK-
10 
IgG2c No 
CHK-
68 
IgG2c Yes CHK-
141 
IgG2c Yes CHK-
215 
IgM/IgG2b No 
CHK-
11 
IgG2c Yes 
CHK-
69.A 
IgG1 Yes CHK-
142 
IgG2c Yes CHK-
216 
N.D. N.D. 
CHK-
12 
IgG2c No 
CHK-
69.B 
IgG2c Yes CHK-
143 
IgG3 No CHK-
217 
IgM No 
CHK-
13 
IgG1 Yes 
CHK-
70 
IgG2c Yes CHK-
144 
IgG2c Yes CHK-
218 
N.D. Yes 
CHK-
14 
IgG2c Yes 
CHK-
71 
IgG2c Yes CHK-
145 
IgG2c Yes CHK-
219 
N.D. N.D. 
CHK-
15 
IgM No 
CHK-
72 
IgG2c Yes CHK-
147 
IgG2b Yes 
CHK-
220 
N.D. N.D. 
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CHK-
16 
N.D. N.D 
CHK-
73 
IgG2c Yes CHK-
148 
IgG2c Yes. 
CHK-
222 
IgG1 No 
CHK-
17 
IgG2c Yes 
CHK-
74 
IgG2c Yes CHK-
149 
IgG2c Yes 
CHK-
223 
IgM No 
CHK-
18 
IgG2c No 
CHK-
75 
IgG1 Yes CHK-
150 
IgG2b Yes 
CHK-
224 
N.D. N.D. 
CHK-
19 
IgG2c No 
CHK-
76 
IgG1 Yes CHK-
151 
IgG2c Yes CHK-
225 
IgM No 
CHK-
20 
N.D. N.D 
CHK-
77 
IgG2c Yes CHK-
152 
IgG2c No CHK-
226 
IgM No 
CHK-
21 
IgM No 
CHK-
78 
IgG2b Yes CHK-
153 
N.D. N.D. CHK-
227 
N.D. N.D. 
CHK-
22 
IgG2b No 
CHK-
79 
IgM/IgG1 Yes CHK-
154 
N.D. N.D. CHK-
228 
N.D. N.D. 
CHK-
23 
N.D N.D CHK-
81 
IgG2c Yes CHK-
155 
IgG2c Yes 
CHK-
229 
IgG1/IgM No 
CHK-
24 
IgG1/IgM 
No CHK-
82 
IgG2c Yes CHK-
156 
IgG2b Yes 
CHK-
230 
IgG1 No 
CHK-
25 
IgG2c Yes 
CHK-
83 
IgG2c Yes CHK-
157 
IgG2b Yes 
CHK-
231 
IgG2c No 
CHK-
26 
N.D N.D 
CHK-
84 
IgG2c Yes CHK-
158 
IgG2c Yes 
CHK-
232 
IgM No 
CHK-
27 
N.D No 
CHK-
85 
IgG2c Yes CHK-
159 
IgG2c Yes 
CHK-
233 
IgM No 
CHK-
28 
N.D No 
CHK-
86 
IgG2c Yes CHK-
160 
IgG2c Yes 
CHK-
234 
IgG1 No 
CHK-
29 
N.D No 
CHK-
87 
IgG1 Yes CHK-
161 
IgG2c Yes 
CHK-
235 
IgG1 No 
CHK-
30 
IgM No 
CHK-
88 
IgG2c Yes CHK-
162 
IgG2c Yes 
CHK-
237 
IgM No 
CHK-
31 
N.D No 
CHK-
89 
IgG2b Yes CHK-
163 
IgG2c Yes 
CHK-
238 
IgM No 
CHK- N.D No CHK- IgM No CHK- IgG2c Yes CHK- IgM weak 
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32 90 164 239 
CHK-
33 
IgG2c No 
CHK-
91 
IgG2c Yes CHK-
165 
IgG2c Yes 
CHK-
240 
IgM No 
CHK-
34 
IgM No 
CHK-
92 
IgG2c No CHK-
166 
IgG2c No 
CHK-
241 
N.D. N.D. 
CHK-
35 
N.D No 
CHK-
94 
IgG2c Yes CHK-
168 
IgG2c Yes 
CHK-
242 
N.D. N.D. 
CHK-
36 
N.D Yes 
CHK-
95 
IgG2c Yes CHK-
169 
IgG2c Yes 
CHK-
243 
N.D. Yes 
CHK-
37 
N.D No 
CHK-
96 
IgG2c Yes CHK-
170 
IgG1 No 
CHK-
244 
IgG2c Yes 
CHK-
38 
IgG2c No 
CHK-
97 
IgG2c Yes CHK-
172 
IgG2c Yes 
CHK-
245 
N.D. weak 
CHK-
39 
N.D N.D 
CHK-
98 
IgG2c Yes CHK-
173 
IgG2c Yes 
CHK-
246 
IgG2c Yes 
CHK-
40 
IgG3 No 
CHK-
99 
IgG2c Yes CHK-
174 
IgG2b Yes 
CHK-
247 
IgG2c Yes 
CHK-
41 
N.D N.D 
CHK-
101 
IgG2b Yes CHK-
175 IgG2c 
Yes 
CHK-
248 
N.D. N.D. 
CHK-
42 
N.D N.D 
CHK-
102 
IgG2c Yes CHK-
176 
IgG2c No 
CHK-
249 
N.D. N.D. 
CHK-
43 
N.D N.D 
CHK-
103 
IgM No CHK-
177 
IgG2c Yes 
CHK-
250 
N.D. N.D. 
CHK-
44 
N.D N.D 
CHK-
104 
IgG2c Yes CHK-
178 
IgG2c Yes 
CHK-
251 
IgG2c Yes 
CHK-
45 
N.D N.D 
CHK-
105 
IgG1 Yes CHK-
179 
IgG2c Yes 
CHK-
256 
IgM No 
CHK-
46 
IgG3 No 
CHK-
106 
IgG2c Yes CHK-
180 
IgG2c Yes 
CHK-
261 
N.D. No 
CHK-
47 
N.D N.D 
CHK-
107 
IgG2c Yes CHK-
181 
IgG1 Yes 
CHK-
262 
IgG2c Yes 
CHK-
48 
IgG2c Yes 
CHK-
108 
N.D. No CHK-
182 
N.D. No 
CHK-
263 
IgG2c Yes 
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CHK-
49 
N.D No 
CHK-
109 
IgG1 Yes CHK-
186 
IgG2c Yes 
CHK-
264 
IgG2c Yes 
CHK-
50 
N.D N.D 
CHK-
110 
IgG2c Yes CHK-
187 
IgG2c Yes 
CHK-
265 
IgG2c Yes 
CHK-
51 
N.D N.D 
CHK-
112 
IgG2c Yes CHK-
188 
IgG2c Yes 
CHK-
266 
IgG2c/IgG1 Yes 
CHK-
52 
IgG1 No 
CHK-
114 
IgG2c No CHK-
189 
IgG2c Yes 
CHK-
267 
IgG2c Yes 
CHK-
53 
IgG2c Yes 
CHK-
117 
IgG2c Yes CHK-
190 
IgG2c Yes 
CHK-
268 
IgG2c Yes 
CHK-
54 
IgG2c Yes 
CHK-
119 
IgG2c Yes CHK-
191 
IgG2c Yes 
CHK-
269 
IgG2b No 
CHK-
55 
IgG2c Yes 
CHK-
122 
IgM No CHK-
193 
IgG2c Yes 
CHK-
270 
IgG2c Yes 
CHK-
56 
IgG2c Yes 
CHK-
124 
IgG2c Yes CHK-
201 
IgG1 Yes 
   
CHK-
57 
IgG2c Yes 
CHK-
125 
N.D. No CHK-
204 
IgG2b Yes 
   
CHK-
58 
IgG2c Yes 
CHK-
126 
N.D. No CHK-
205 
IgG2b No 
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Table S2. Cross-neutralization of infection by wild type and mutant SFV-CHIKV 
infection with anti-CHIKV MAbs 
 
Selecting 
MAb 
CHIKV 
variant 
Test MAb Test MAb Test MAb Test MAb 
  CHK-102 CHK-152 CHK-166 CHK-263 
CHK-102 E2 L210P Resistant Sensitive N.D. Resistant 
CHK-102 E2 G209E Resistant Sensitive N.D. Resistant 
      
CHK-152 E2 D59N Sensitive Resistant N.D. Sensitive 
CHK-152 E2 A89E Sensitive Sensitive N.D. Sensitive 
      
CHK-166 E1 K61T N.D. N.D. Resistant N.D. 
CHK-166 E1 P74A N.D. N.D. Sensitive N.D. 
      
CHK-263 E2 K215E Resistant Sensitive N.D. Resistant 
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Table S3. VH and VL nucleotide and protein sequences of protective anti-CHIKV MAbs 
A. CHK-102 
CHK-102-VH 
atgggatggagctgtatcatgttcttcctcctgtcaggaactgcaggtgtccaatccCAGGTTCAGCTGCAGCAG
TCTGGGGCTGAGCTGGTGAAGCCTGGGGCCTCAGTGAAGATTTCCTGCAAAA
CTTCTGGCTACGCATTCAGTAGTTTCTGGATGCACTGGGTGAAGCAGAGGCCT
GGAAAGGGTCTTGAGTGGATTGGACAGATTTATCCTGGAGATGGTGATACTA
ACTATAACGGAAAGTTCAAGGACAAGGCCACACTGACTGCAGACAAATCCTC
CAACACAGCCTACATGCAGCTCACCAGCCTGACCTCTGAGGACTCTGCGGTC
TATTTCTGTGCAAGAAACTTACTTTTTGACTACTGGGGCCAAGGCACCACTCT
CACAGTCTCCTCA 
MGWSCIMFFLLSGTAGVQSQVQLQQSGAELVKPGASVKISCKTSGYAFSSFWMH
WVKQRPGKGLEWIGQIYPGDGDTNYNGKFKDKATLTADKSSNTAYMQLTSLTS
EDSAVYFCARNLLFDYWGQGTTLTVSS 
CHK-102-VL 
GAGATCCTGATGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAA
GAGTCAGTTTCTCCTGCAGGGCCAGTCAGAGCATTGGCTCAAACATACACTG
GTATCAGCAAAGAACAAATGGTTCTCCAAGGCTTCTCATAAAGTATGCCTCT
GAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGGTCAGGGACAG
ATTTTACTCTTAGCATCAACAGTGTGGAGTCTGAAGATATTGCAGATTATTAC
TGTCAACAGAATAATATCTGGCCATTCACGTTCGGCTCGGGGACAAAGTTGG
AAATAAAG 
EILMTQSPAILSVSPGERVSFSCRASQSIGSNIHWYQQRTNGSPRLLIKYASESISGI
PSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNIWPFTFGSGTKLEIK 
 
B. CHK-152 
CHK-152-VH 
atgggatggagctgtatcatcctcattttggtagcagcagctacaggtgtccactccCAGGTCCAGCTGCAGCAG
CCTGGGGCTGCGCTTGTGAAGCCTGGGGCTTCAGCGATGATGTCCTGCAAGG
CTTCTGGCTACACCTTCACCAGCTACTGGATAACCTGGGTGAAGCAGAGGCC
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TGGACAAGGCCTTGAATGGATTGGGGACATTTACCCTGGTACTGGTCGAACT
ATCTACAAGGAGAAGTTCAAGACCAAGGCCACACTGACTGTAGACACATCCT
CCAGCACAGCCTTCATGCAGCTCAACAGCCTGACATCTGAGGATTCAGCGGT
CTATTACTGTGCAAGAGGCTACGGTAGTCCTTACTATGCTTTGGACTACTGGG
GTCAAGGAACCTCAGTCACCGTCTCCTCA 
MGWSCIILILVAAATGVHSQVQLQQPGAALVKPGASAMMSCKASGYTFTSYWIT
WVKQRPGQGLEWIGDIYPGTGRTIYKEKFKTKATLTVDTSSSTAFMQLNSLTSED
SAVYYCARGYGSPYYALDYWGQGTSVTVSS 
CHK-152-VL 
atggagacagacacaatcctgctatgggtgctgctgctctgggttccaggctccactggtGACATTGTGCTGACCC
AATCTCCAGCTTCTTTGGCTGTGTCTCAAGGGCAGAGGGCCACCATCTCCTGC
AAGGCCAGCCAAAGTGTTGATTATGATGGTGATAGTTATGTGAACTGGTACC
AACAGAAACCAGGACAGTCACCCAAACTCCTCATCTATGATGCATCCAATCT
AGAATCTGGGATCCCAGCCAGGTTTAGTGGCAGTGGGTCTGGGACAGACTTC
ACCCTCAACATTCATCCTGTGGAGGAAGAGGATGTTGCAACCTATTACTGTCA
GGAAAGTAATGAGGATCCTCGGACGTTCGGTGGAGGCACCAAGCTGGAAATC
AAA 
METDTILLWVLLLWVPGSTGDIVLTQSPASLAVSQGQRATISCKASQSVDYDGDS
YVNWYQQKPGQSPKLLIYDASNLESGIPARFSGSGSGTDFTLNIHPVEEEDVATY
YCQESNEDPRTFGGGTKLEIK 
 
C. CHK-166 
CHK-166-VH 
atgaacttggggctcagcttgattttccttgtccttgttttaaaaggtgtccagtgtGAAGTGAGGCTGGTGGAGT
CTGGGGGAGGCTTAGAGCAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGC
CTCTGGATTCACTTTCAGTGACTATTTCATGTATTGGGTTCGCCAGACTCCAG
AGAAGAGGCTGGAGTGGGTCGCATATATTAGTAATGGTGGTATTAGTACCTT
TTATTCAGACGCTGTTAAGGGCCGATTCACCATCTCCAGAGACAATGCCAGG
AACACCCTATACCTACAAATGAGTCGTCTGAAGTCTGAGGACACAGCCATAT
ATTACTGTGTAAGACAGGTCTACGGTCAGGGCTACTTTGACTACTGGGGCCA
AGGCACCACTCTCGCAGTCTCCTCA 
MNLGLSLIFLVLVLKGVQCEVRLVESGGGLEQPGGSLKLSCAASGFTFSDYFMY
WVRQTPEKRLEWVAYISNGGISTFYSDAVKGRFTISRDNARNTLYLQMSRLKSE
DTAIYYCVRQVYGQGYFDYWGQGTTLAVSS 
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CHK-166-VL 
atggattttcaggtgcagattttcagcttcctgctaatcagtgcctcagtcataatgtccagaggaCAAATTGTTCTCAT
CCAGTCTCCAGCGATCATGTCTGCGTCTCTAGGGGAACGGGTCACCATGACC
TGCACTGCCAGCTCAAGTGTAAGTTCCAGTTACTTGCACTGGTACCAGCAGA
AGCCAGGATCCTCCCCCAAACTCTGGATTTATAGTTCATTCAGCCTGGCTTCT
GGAGTCCCAGCCCGGTTCAGTGGCAGTGGATCTGGGACCTCTTACTCTCTCAC
AATCAGCACCATGGAGGCTGAAGATGCTGCCACGTATTACTGCCACCAGTAT
TTGCGTTCCCCGTGGACGTTCGGTGGAGGCTCCAAGCTGGAAATCAAA 
MDFQVQIFSFLLISASVIMSRGQIVLIQSPAIMSASLGERVTMTCTASSSVSSSYLH
WYQQKPGSSPKLWIYSSFSLASGVPARFSGSGSGTSYSLTISTMEAEDAATYYCH
QYLRSPWTFGGGSKLEIK 
 
D. CHK-263 
CHK-263-VH 
atggaatggcctttgatctttctcttcctcctgtcaggaactgcaggtgtccaatccCAGGTTCAGCTGCAGCAGT
CTGGGGCTGAGCTGGTGAAGCCTGGGGCCTCAGTGAAGATTTCCTGCAAAGC
TTCTGGCTACGCATTCAGTAGCTACTGGATGAACTGGGTGAAGCAGAGGCCT
GGAAAGGGTCTTGAGTGGATTGGACAGATTTATCCTGGAGATGGTGATACTA
ACTACAACGGAAAGTTCAAGGGCAAGGCCACACTGACTGCAGACAAATCCTC
CAGCACAGCCTACATGCAGCTCAGCAGCCTGACCTCTGAGGACTCTGCGGTC
TATTTCTGTGCAAGAGGAGGTCTAACTATTGACTACTGGGGCCAAGGCACCA
CTCTCACAGTCTCCTCA 
MEWPLIFLFLLSGTAGVQSQVQLQQSGAELVKPGASVKISCKASGYAFSSYWMN
WVKQRPGKGLEWIGQIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTS
EDSAVYFCARGGLTIDYWGQGTTLTVSS 
CHK-263-VL 
atggtatccacacctcagttccttggacttatgcttttttggatttcagcctccagaggtGATATTGTACTGACTCAG
TCTCCAGCCACCCTGTCTGTGACTCCAGGAGATAGCGTCAGTCTTTCCTGCAG
GGCCAGCCAAAGTATTAGCGACAACCTACACTGGTATCAACAAAAATCACAT
GAGTCTCCAGGGCTTCTCATCAAGTATGCTTCCCAGTCCATCTCTGGGATCCC
CTCCAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACTCTCAGTATCAAC
AGTGTGGAGACTGAAGATTTTGGAATGTATTTCTGTCAACAGAGTAACAGCT
GGCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA 
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MVSTPQFLGLMLFWISASRGDIVLTQSPATLSVTPGDSVSLSCRASQSISDNLHW
YQQKSHESPGLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSN
SWPYTFGGGTKLEIK 
 
The VH and VL variable domains were amplified from hybridoma cell RNA by a 5' 
RACE procedure. Underlined nucleotides and amino acids correspond to the signal 
sequences, when obtained. 
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Table S4. Primers used for sequencing and amplifying the structural genes of CHIKV-
LR 2006-OPY1. 
 Sequencing Primer  5'-Sequence-3' 
1: 5'-8248F  GTCTTAGGAGGAGCTAATGAAGGAG 
2: 5’-8573F CCACAAGACCATACTTAGCTCACTGTCC 
3: 5'-8912F CATGTACGCACCCATTTCACC 
4: 5'-9224F CGGTCACCAATCACAAAAAGT 
5: 5'-9500F CCGTGCCGACTGAAGGG  
6 5'-9802F GCTAAAGCGGCCACATACC 
7: 5'-10101 CACTTTGGAGCCAACACTATCG 
8: 5'-10389 GCTCCGCGTCCTTTACCA 
9: 5'-10676 CGGTACACGTGCCATACTCTCAGG 
                     10: 5'-11017 GCTGAGATAGAAGTTGAAGGGA 
 
PCR Primer  5'-Sequence-3' 
5'-8248F GTCTTAGGAGGAGCTAATGAAGGAGCCCGT 
5'-11359R GTGTGTCTCTTAGGGGACACATATACCTTCATACTT 
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Conclusions 
In this study, we have identified, cloned, and begun characterization of 230 novel CHIKV 
MAbs produced from mice immunized with the epidemic strain, CHIKV-LR 2006 OPY1. 
Thirty-six of these MAbs are neutralizing; over half of them potently inhibit strains representing 
all three distinct genotypes of CHIKV. Many of these MAbs were protective in both a lethal and 
arthritis model of CHIKV infection and four MAbs (CHK-102, CHK-152, CHK-166 and CHK-
263) prophylactically protected all IFNAR-/- mice against death. We sought to define the 
functional epitopes of highly neutralizing anti-CHIKV MAbs and to identify correlates of 
humoral protection. To functionally map protective MAbs, we selected for escape mutants in 
vitro and also isolated mutant CHIKVs in vivo.  
We characterized the first MAb targeting the E1 glycoprotein of CHIKV (CHK-166); 
although this MAb was not as potently neutralizing in vitro, it was still highly effective in vivo. It 
binds to domain II of E1, adjacent to the conserved fusion loop. CHK-102 and CHK-263 target 
domain B of E2; escape mutants selected against one of these two MAbs were always 
reciprocally resistant. Combination therapy with CHK-102 and CHK-263 was not more effective 
than monotherapy, further supporting our hypothesis that MAb therapy targeting different 
epitopes is protective because it prevents the emergence of escape mutants. We determined that 
our most potent MAb, CHK-152, inhibits fusion of CHIKV with lipid membranes and targets 
domain A of E2. Although neutralization alone can protect the majority of mice when an 
aglycosyl N297Q variant of CHK-152 (lacking the ability to engage effector functions) is 
administered, it is still more protective when effector functions are recruited, especially at lower 
doses of MAb. While CHK-152 neutralization was not enhanced by CHK-102, CHK-166 or 
CHK-263 in vitro, its protective capacity was certainly augmented in vivo. Indeed, combination 
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monoclonal antibody therapy with MAbs that target different epitopes on E1 and E2 was 
protective against CHIKV-induced death in IFNAR-/- mice. 
With the globalization of diseases and spread of mosquito vectors, the need for 
development of a CHIKV vaccine has increased. Currently, no licensed human vaccine exists for 
CHIKV and mosquito control is the only reliable means of preventing infection. Since sera from 
convalescent CHIKV infected patients or CHIK virus-like particle (VLP) vaccinated primates 
can prevent and cure an otherwise lethal infection in IFNAR-/- mice [1,2], we believe an epitope-
directed vaccine may be possible. This study leaves us with many exciting questions and 
directions, some of which we have begun to address. 
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Future Directions 
There are 29 different alphaviruses distributed throughout the world; the Semliki Forest 
virus antigenic complex consists of CHIKV and seven other related alphaviruses [3]. Many are 
endemic in Africa and Asia, where CHIKV epidemics have been reported for centuries. CHIKV 
is serologically most closely related to O’nyong’nyong virus (ONNV), which causes a similar 
debilitating, arthritic fever. In fact, the term “O’nyong’nyong” describes a weakening of the 
joints in the Nilotic language of Uganda where an epidemic began in the late 1950s and spread of 
many neighboring countries, affecting about two million people [4]. ONNV and CHIKV are 
similar genetically and share 72% nucleotide homology and 87% amino acid homology [5] but 
phylogenetic analysis indicates that these two viruses probably diverged thousands of years ago 
[6]. Additionally, ONNV is the only alphavirus transmitted by Anopheles mosquitoes, which are 
widely known as the vector for transmission of malaria-causing Plasmodium species [7]. Mayaro 
virus causes a disease indistinguishable from that caused by ONNV, but has been found only in 
South America, or in travelers returning from this region [6,8]. 
 Based on the antigenic and phylogenetic relatedness of many of these alphaviruses to 
CHIKV (Figure 1), it is possible that some of our CHIKV MAbs cross-react with or even 
neutralize some of these other alphaviruses. We began to study this by growing stocks of ONN, 
Ross River, Semliki Forest, Mayaro, Una, Getah, Bebaru, Middleburg, Barmah Forest, Sindbis 
and Venezuelan equine encephalitis viruses. We tested for cross-reactivity between the 36 
neutralizing CHIKV MAbs and two non-neutralizing MAbs against the eleven alphaviruses by 
flow cytometry, as described in the methods. We also tested another strain of CHIKV, CHIKV-
Ross, representing the ECSA genotype prior to the emergence of La Reunion epidemic strain, 
which is known to contain many mutations in the structural genes. All of the MAbs, including 
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the non-neutralizing MAbs CHK-84 and CHK-141 cross-reacted with CHIKV-Ross (Figure 2). 
CHK-266 was the only MAb tested that failed to bind to one of the strains of CHIKV; it showed 
no reactivity to CHIKV-RSU1, the Asian strain, and also did not cross-react to any of the other 
alphaviruses. The epitope for this MAb appears to be restricted to the African lineage of 
CHIKVs and will be interesting to explore further with mapping studies.  
Seventeen of the neutralizing MAbs strongly cross-reacted (50-100% of infected cells 
bound MAb as judged by flow cytometry) and ten moderately cross-reacted (10-50% of infected 
cells bound MAb) with ONNV. As demonstrated previously, CHK-263 and CHK-102 are both 
potent, protective E2 domain B MAbs, as determined by functional mapping experiments; 
however, CHK-102 strongly cross-reacts with ONNV but CHK-263 does not recognize ONNV. 
Neither of these MAbs binds to any of the other alphaviruses tested. It will be interesting to 
further explore how the epitopes for these two MAbs differ since they both neutralize all three 
strains of CHIKV (LR, RSU1 and IbH35) with comparable potency and completely protect 
IFNAR-/- mice prophylactically against CHIKV-LR infection at the 100 µg dose. However, 
CHK-263 is more protective than CHK-102; this is apparent when lower doses are used. Perhaps 
the CHIKV epitope specificity of this MAb contributes to its enhanced protective potential. 
Neutralization of ONNV should be explored by performing neutralization assays with the MAbs 
that cross-react with this virus. This may lend insight into the functional significance of shared 
epitopes between these two related alphaviruses.  
Just a few of the CHIKV neutralizing MAbs cross-reacted with seven or more of the 
alphaviruses tested: CHK-166, CHK-180, CHK-187 and CHK-265 (Figure 2). Cross-reactivity 
with many such diverse viruses suggests that these four MAbs target an epitope that is conserved 
amongst the alphaviruses. From escape mutant analysis we know that CHK-166 binds to a highly 
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conserved region of domain II of E1. Further studies into CHK-180, CHK-187 and CHK-265 
may define other highly conserved alphavirus epitopes. Neutralization experiments performed by 
our collaborators (Ted Pierson, NIH, unpublished data) demonstrate that CHK-65, CHK-77, 
CHK-88 and CHK-124 also neutralize Semliki Forest virus (SFV) in a dose-dependent fashion. 
They did not test CHK-187, which is the only other strongly cross-reactive MAb against SFV. 
These results are exciting because all of the MAbs tested that efficiently cross-reacted to SFV 
also neutralized infection. This suggests that it may be promising to test the other alphaviruses 
that strongly bind CHK MAbs for neutralization potential.  
Cross-reactivity appears to correlate with the genetic relatedness of the alphaviruses. 
Middleburg and Barmah Forest viruses are assigned to two separate antigenic complexes and 
displayed only limited cross-reactivity with these CHK-MAbs. Only two MAbs, CHK-96 and 
CHK-98, moderately cross-react with Venezuelan equine encephalitis virus (VEEV), a more 
distantly related New World Alphavirus.  
It also will be informative to functionally map all of the neutralizing anti-CHIKV MAbs 
and develop a more global structural picture of neutralization. We have begun working on this by 
using an NNN codon mutagenesis strategy. Primer pairs incorporating NNN at the amino acid of 
interest will be designed, so there will be 64 primer pairs per amino acid selected. Theoretically 
speaking, to completely map these antibodies we would need to make NNN mutations for each 
codon of the 1,100 amino acids in E1, E2 and E3 by designing and using an NNN primer set for 
every amino acid. We can target candidate amino acids by choosing those that fulfill certain 
characteristics including high conservation amongst alphaviruses, variation among CHIKV 
strains, or surface exposed or hydrophilic residues based on existing crystal and cryo-electron 
microscopy structures [9,10]. It is possible that rare MAbs inhibit infection by binding to regions 
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that are exposed only at certain times in the viral replication cycle, such as homo-trimerization or 
the removal of the E2-Domain B cap from the fusion loop. The relevance of these regions in 
neutralization may be missed if only surface exposed residues are selected, so it may be prudent 
to revisit mapping of any MAbs that were unaffected by the amino acids initially mutated.  
In preliminary experiments, we screened 38 anti-CHIKV MAbs against CHIKV encoding 
a point mutation (see methods) that conferred resistance to CHK-152 or CHK-166 (E2: D59N 
and E1: K61T, respectively); these mutant viruses were tested first since CHK-152 and CHK-
166 were the most protective in vivo. We were interested in determining whether any of the other 
MAbs in our repertoire require either of these residues and perhaps share an epitope with these 
potent MAbs. While none of the 38 MAbs (besides CHK-152) were incapable of neutralizing 
CHIKV-D59N, CHK-180 and CHK-269 were unable to neutralize CHIKV-K61T, even at a high 
MAb concentration of 10 µg/mL. This indicates that residue K61T also is important for efficient 
neutralization by CHK-180 and CHK-269. Since CHK-166 and CHK-180 have identical cross-
reactivity and neutralization profiles, it is possible that they share a large portion of their epitope.  
Further study into the antibody response of seropositive, asymptomatic individuals also is 
warranted. Most people that are infected with CHIKV develop acute symptoms of disease, 
including fever, arthralgia, and myalgia. However, small subsets of people have been identified 
on La Reunion and in Kerala, India, that are seropositive for CHIKV but failed to develop 
symptoms consistent with CHIKV disease [11,12]; this indicates that prevalence of 
asymptomatic, seropositive people is not regionally restricted. It will be interesting to investigate 
the quality and kinetics of the antibody response generated by asymptomatic individuals. It is 
possible that they produced highly neutralizing antibodies that, in conjunction with a rapid innate 
immune response, clear CHIKV before the infection became fully established. CHIKV spreads 
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widely in naïve populations; on the island of La Reunion over a third of the population 
(~300,000 people) was infected, so identifying  seropositive, asymptomatic individuals should be 
straightforward [13-15]. It is also possible that asymptomatic individuals lack a necessary co-
factor or receptor in particular cells (akin to a CCR5∆30 mutation in patients exposed to HIV 
who do not develop disease), which may render the environment resistant to CHIKV infection. 
Another possible explanation for why a subset of people did not exhibit any apparent clinical 
symptoms of CHIKV disease is that they previously generated cross-reactive antibodies against a 
related alphavirus. In this case, upon CHIKV infection, memory B cells would re-activate, 
differentiate, and secrete antibodies that help to rapidly clear infection. A complete history of 
febrile, arthritic diseases and the persistence of previous joint pain in this population will be 
important to note. Nevertheless, it may be informative to understand how the antibody response 
of asymptomatic, seropositve people differed from those that became ill. Epitopes targeted by 
potent antibodies in the former may help inform vaccine design. 
Examining differences between the antibody responses of patients that do or do not 
develop chronic arthritis also may be enlightening. Patient studies have correlated a more severe, 
acute disease with early, high viremia but this group also developed an early IgG3 response and 
completely cleared CHIKV infection without persistent arthralgia [16]. In fact, none of the 
patients producing early IgG3 (7- 10 days after the onset of infection) in this study developed 
persistent arthrlagias, but 30% of late IgG responders did [16]. While acute CHIKV is a painful 
and debilitating illness, it is usually self-limited and resolves within two weeks; arguably, the 
most significant morbidity occurs during the chronic stages, during which symptoms may linger 
and recur for months to years. While kinetics of the antibody response appear to contribute to 
disease pathogenesis or restriction, the quality of this response may be important. Further 
108 
 
investigation into epitopes targeted by late IgG responders that do not develop chronic illness 
may be informative. B cells from consenting, convalescent patients with a history of persisting 
arthralgias and with no chronic illness could be harvested and immortalized so that the 
neutralization potential of their antibody response and epitopes targeted by these MAbs can be 
studied.  
 CHK-152 or CHK-166 completely protected IFNAR-/- mice prophylactically, but a lower 
dose of CHK-152 protected 75% of mice. A lower dose of CHK-166, however, failed to protect 
any mice, and they all died at 7 days post infection. Independently, CHK-152 and CHK-166 
were partially protective when administered one day post CHIKV infection. We identified 
CHIKV escape mutants, including the E2-D59N mutation, in the leg muscle and brains of mice 
that died despite CHK-152 treatment, but only sequenced wild-type virus from tissues harvested 
from mice prophylactically treated with CHK-166. Tissue was harvested from one mouse that 
died despite CHK-166 therapeutic treatment, and we discovered a novel mutation that conferred 
complete resistance to neutralization by CHK-166, E1-G64S. When we selected for escape 
mutants to CHK-166 in vitro, all plaques sequenced featured the mutation E1-K61T; however, 
this mutation was not isolated in vivo. Combination therapy with CHK-166 and CHK-152 was 
completely protective earlier in the course of infection in IFNAR-/- mice, but less effective when 
administered 24 to 36 hours before death. However, our sequencing studies from mice dying 
despite combination therapy never defined a double mutant (ie D59N + K61T) or a novel 
mutation conferring complete resistance to the respective MAbs. As such, we have begun to test 
the potential fitness costs of the E2-D59N, E1-K61T and E2-D59N + E1-K61T mutations on 
CHIKV. To assess this, we introduced these mutations into CHIKV-LR 2006 OPY1 infectious 
clone, to generate isogenic viruses. After generating passage 0 stocks by electroporation of 
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mammalian cells and passage 1 insect cell stocks, we have begun performing growth curves on 
mammalian and insect cells. We have not observed any difference in the growth of the D59N or 
K61T viruses, but studies are ongoing. We are being careful to maintain the cells in medium 
containing CHK-152, CHK-166 or both CHK-152 and CHK-166 to prevent reversion to the 
wild-type virus.  
Fitness experiments also have been performed in mice, and while all three viruses 
(delivered to mice that were treated with the respective MAb to prevent reversion and to 
untreated mice) are lethal in the IFNAR-/- model, the mice infected with the double mutant and 
treated with CHK-152 and CHK-166 survived a few days longer before succumbing to death 
(data not shown). This suggests that in vivo, there may be a fitness cost to CHIKV for 
maintaining both these mutations. Collaboratively, with the Higgs laboratory, we are testing the 
effect of these three mutations on CHIKV fitness in their Aedes mosquito vector. Unlike other 
viruses, arboviruses undergo unique selective pressure that occurs with infection of vertebrate 
and invertebrate hosts. As such, fewer mutations are generally observed amongst alphavirus 
genomes than in other RNA viruses [17], presumably due to purification of genomic changes 
that yield fitness costs in a given species. We are interested in investigating whether these 
mutations that confer resistance to MAbs CHK-152 and CHK-166 are purified in mosquito 
populations; this has important implications for possible MAb-based therapy. It has previously 
been shown that Aedes albopictus midgut infectivity was enhanced by a single point mutation 
E1-A226V [18] and that aspartic acid (D) at amino acid 60 on E2 is an important determinant of 
Aedes aegypti and Aedes albopictus infectivity [19]. This latter mutation is directly adjacent to 
E2-D59N mutation that we are testing.  
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As another step towards a potential combination MAb therapy for patients, therapeutic 
treatment of non-human primates was performed by our collaborators (Dan Streblow, OHSU). 
These studies show a decrease in viremia and viral dissemination after treatment with CHK-152 
and CHK-166.  Thus, it is possible that there could be a future role of MAb based prophylaxis or 
therapy in target populations including pregnant women, infants, and patients with certain pre-
existing co morbidities that are vulnerable to serious CHIKV-induced complications [20-23].  
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Materials  and methods  
Cross-reactivity of CHIKV antibodies. CHIKV MAbs were tested for cross-reactivity 
against a panel of non-CHIKV arthritogenic alphaviruses available from the World Arbovirus 
collection (generous gift of R. Tesh, Galveston, TX) and a single New World encephalitic 
alphavirus. This panel included the following viruses, which were passaged once in Vero76 or 
Vero T144 cells: Una (CO AR), Mayaro (BE H 407), Semliki Forest (M4862), Sindbis (AR339), 
Getah (AMM-2021), Barmah (K 10521), O'nyong-nyong (MP30), Middleburg (30037), Ross 
River (T48) and Venezuelan equine encephalitis (TC-83) viruses. Vero cells were infected with 
each virus (MOI of 0.01 for 12 to 24 hours, depending on the virus), harvested with HBSS 
supplemented with 3 mM EDTA, fixed with 1% PFA in PBS for 8 minutes, and permeabilized 
with 0.1% (w/v) saponin detergent solution in HBSS. Approximately 105 cells were incubated 
with different CHIKV MAbs (10 µg/mL solution) for 60 minutes on ice. After washing, cells 
were then incubated with 4 µg/mL of Alexa 647 anti-mouse IgG secondary antibody 
(Invitrogen), evaluated on a FACSArray flow cytometer (Becton-Dickinson) and analyzed using 
FlowJo software (Tree Star). 
 Cells and viruses. Vero cells and BHK21-15 cells were cultured in DMEM (Dulbecco’s 
modified Eagle medium) supplemented with 5% or 10% fetal bovine serum, respectively, (FBS) 
(Omega Scientific), 10 mM HEPES, nonessential amino acids (Cellgro) and antibiotics 
(penicillin and streptomycin G) at 37oC in a 5% CO2 incubator. C6/36 Aedes albopictus cells 
were grown in Leibovitz-15 media (Gibco) supplemented with 10% FBS, 10 mM HEPES, and 
antibiotics (penicillin and streptomycin G) at 27oC. The infectious clone of CHIKV LR 2006 
OPY-1 (strain 142) was a generous gift from S. Higgs (Galveston, TX). Plasmids containing the 
wild-type CHIKV structural genes or single point mutations, CHK struct- pDonor221, were a 
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generous gift from T. Pierson (NIAID). Single point mutations were introduced into the 
infectious clone by ligating a SgrA1 (New England Biolabs) and Sfi1 (New England Biolabs) 
double digested CHK struct- pDonor221fragment containing the respective mutation, into the 
SgrA1 and Sfi1 double digested infectious clone. The double mutant D59N+K61T-142 was 
created by performing a mutagenesis reaction on the D59N-142 plasmid with primers : 
Forward -  gtctccgtacgtgacgtgctgcggtacag 
Reverse  -  ctgtaccgcagcacgtcacgtacggagac 
 
To produce virus from infectious clones, plasmids were linearized and RNA was produced using 
an SP6 DNA-dependent RNA polymerase transcription kit following the manufacturer’s 
instructions (mMessage kit; Ambion). CHIKV RNA was electroporated into BHK21-15 cells 
and supernatant was harvested 28 hours later, aliquoted, and frozen at -80oC. C6/36 cells were 
infected with this P0 CHIKV-LR at an MOI of 0.01, in the presence of 10 µg/mL of either CHK-
166 for K61T-142, CHK-152 for D59N-142 and 10 µg/mL of both CHK-166 and CHK-152 for 
the D59N+K61T-142 double mutant. Supernatant was harvested 68- 72 hrs later. Virus was 
titered on Vero cells by focus forming unit (FFU) assay.  
 
Neutralization assays. MAb neutralization of CHIKV was assessed by an FFU assay. 
Eleven three-fold serial dilutions of MAb (ranging from 10 µg/ml to ~1 ng/ml in 2% DMEM) 
were incubated with ~102 FFU of CHKV for one hour at 37oC. MAb-virus complexes were 
added to a monolayer of African monkey Vero cells (seeded overnight at 3 X 104 cells/well, in 
96-well plates) in 5% DMEM. Cells were infected at 37oC for 90 minutes, and overlaid with 1% 
(w/v) methylcellulose in Modified Eagle Media (MEM) supplemented with 4% FBS. Plates were 
harvested 18 and fixed with 1% (w/v) paraformaldehyde in PBS. The plates were incubated 
sequentially with 500 ng/ml of a chimeric CHK-9 MAb (chCHK9) and a 0.3 mg/ml solution of 
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HRP-conjugated goat anti-human IgG secondary antibody (Sigma) in PBS supplemented with 
0.1% saponin and 0.1% BSA. CHIKV-infected foci were visualized using TrueBlue peroxidase 
substrate (KPL) and quantitated on an ImmunoSpot 5.0.37 macroanalyzer (Cellular Technologies 
Ltd). Non-linear regression analysis was performed, and EC50 values were calculated using 
Prism compared to wells infected with CHIKV in the absence of antibody. 
 
Growth Curves  Vero cells were seeded overnight at 6 X 104 cells/well in 12 well plates 
in 1mL of DMEM containing 5% FBS. C6/36 cell-derived CHIKV mutants or WT CHIKV were 
incubated with 10 µg/mL of CHK-166, CHK-152, both CHK-166 and CHK-152 or no MAb for 
1 hour at 37°C. Media was removed from Vero cells and they were infected with 500 µL of 
inoculum for 1 hour at 37°C. After the hour, inoculum was removed and cells were washed with 
PBS. Media containing the respective MAb or no MAb was added back to the cells. Time points 
were harvested at 1, 12, 24 and 36 hours post-infection. Similarly, growth curves were performed 
on C6/36 cells with P0 BHK-derived CHIKVs and time points were harvested at 1, 24, 48 and 72 
hours post-infection. Virus was titered by FFU assay. Experiments were performed in triplicate 
three times. 
 
Mouse Experiments. IFNAR-/- C57BL/6 mice were obtained from J. Sprent (Scripps 
Institute, San Diego CA), backcrossed ten times onto the C57BL/6 background, and bred in the 
pathogen-free animal facilities of Washington University School of Medicine. Experiments were 
performed with the approval of the Washington University Animal Studies Committee. To 
prevent mutant CHIKV reversion, some mice were treated pre-exposure with 100 µg of either 
CHK-152, CHK-166 or both CHK-152 and CHK-166. MAbs were administered by 
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intraperitoneal (IP) injection into 6 to 8 week old IFNAR-/- mice. Twenty-four hours later, mice 
were inoculated in the footpad with 10 FFU of C6/36 cell derived D59N-142, K61T-142, 
D59N+K61T-142, or CHIKV-LR in 50 µl of Hanks balanced salt solution (HBSS) supplemented 
with 1% heat-inactivated FBS.  
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Figure Legends 
 
Figure 1. This figure is borrowed from Powers, 2001 [6].  Phylogenetic relationship of most 
Alphaviruses species, generated from partial E1 envelope protein sequences. The open circle 
adjacent to a branch indicates hypothetical Old to New World introduction, and the closed circle 
indicates New to Old World introduction, assuming a New World origin; the open square 
indicates Old to New World introduction, and the closed square indicates New to Old World 
introduction, assuming an Old World origin of the nonfish Alphavirus clade. 
 
Figure 2. Cross-reactivity of Alphaviruses with 38 anti-CHIKV MAbs. Vero76 cells were 
infected at an MOI of 0.01, fixed and permeabilized. These cells were stained with 10 µg/mL of 
the anti-CHIKV MAbs. The viruses are listed in order from least to most divergence from 
CHIKV-LR. (++) denotes strong binding, 50-100 % of cells stained with this MAb. (+) denotes 
moderate binding, 10-50% of cells stained with this MAb. (-) denotes no binding, <10% of cells 
bound this MAb. Immune sera refers to a 1:1000 dilution of serum harvested from mice that 
were immunized with CHIKV-LR. 
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present analyses are also consistent with this hypothesis. Ex-
cluding the fish and seal viruses, a New World origin would
require at least three transoceanic introductions between the
hemispheres: (i) transport of the ancestor of the Barmah For-
est-Ndumu-Middelburg-Semliki Forest virus complexes from
the New World to the Old World, (ii) transport of the ancestor
of the Sindbis and Whataroa viruses to the Old World, and (iii)
transport of the ancestor of the Mayaro and Una viruses from
the Old World to the New World (Fig. 2). However, an Old
World origin is also consistent with three transoceanic intro-
ductions between the hemispheres: (i) transport of the ances-
tor of the Trocara virus-WEE-EEE-VEE complexes from the
Old World to the New World; (ii) transport of the ancestor of
the Sindbis and Whataroa viruses to the Old World, and (iii)
transport of the ancestor of the Mayaro and Una viruses from
the Old World to the New World (Fig. 2). These equally par-
simonious scenarios do not favor either hypothesis over the
other. An ancestral alphavirus presumably adapted to fish in
the distant past to form the SDV-SPDV lineage. The possible
transmission of SESV by insects (lice) strengthens the hypoth-
esis that alphaviruses arose as insect-borne or insect viruses.
Previous estimates placed the origin of the alphaviruses sev-
eral thousand years ago (73, 79). However, the methods em-
ployed previously relied on the assumption of an equal rate of
substitutions across nucleotide or amino acid positions in the
alphavirus genome. Our data clearly indicate that this assump-
tion is invalid; all estimates of the uniformity of nucleotide
changes across sites are far from uniform, with an average
gamma value of only 0.24 for those viruses examined in detail
(range, 0.05 to 0.31). This nonuniformity in nucleotide substi-
tutions across sites, combined with the saturation of nucleotide
changes in many positions, indicates that estimates on the
order of thousands of years ago for the alphavirus ancestor are
far too recent. An accurate time estimate for the alphavirus
progenitor may be impossible due to these factors. Another ex-
ample of the problems with estimating internal branch lengths
is illustrated by our analysis of the recombination event be-
tween EEEV- and Sindbis virus-like ancestors leading to the
WEEV Fort Morgan virus-Highlands J virus group (19, 80).
The interior branch lengths produced with most of the phylo-
genetic methods yielded different horizontal positions for the
internal branches shown previously to represent the recombi-
nant ancestors (80) (Fig. 2). The fact that these ancestors did
not occur at the same horizontal position (the dashed line in
Fig. 2 cannot be drawn vertically) indicates error in the internal
FIG. 2. Phylogenetic tree of all Alphavirus species, and selected subtypes and variants, generated from partial E1 envelope glycoprotein gene
sequences by using the neighbor-joining program with the F84 distance formula (61). Virus abbreviations are found in Table 1, footnote 6.
Numbers refer to bootstrap values for clades defined by the adjacent node. The topology of Cabassou virus (CABV) and Pixuna virus (PIXV)
within the VEEV complex was constrained based on the more robust results of the complete structural polyprotein sequence analysis (see Fig. 3),
and this topology was not significantly less likely based on maximum-likelihood analyses with the E1 gene sequences. The open circle adjacent to
a branch indicates hypothetical Old to New World introduction, and the closed circle indicates New to Old World introduction, assuming a New
World origin; the open square indicates Old to New World introduction, and the closed square indicates New to Old World introduction, assuming
an Old World origin of the nonfish Alphavirus clade.
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Extracurricular Activities 
 
2012- 2010 Molecular Microbiology and Microbial Pathogenesis Program Student 
Representative 
2011- 2008 Choreographer/Dancer/Organizer Medical School Class Show 
2009- 2008 Choreographer/Cast Medical School Musical 
2010-2008 Volunteer at Saturday Neighborhood Free Health Clinic 
2010- 2009 Teaching Assistant for Medical Physiology 
2009 Course Liaison for Infectious Diseases 
2009 Course Liaison for Psychiatry 
2009-2008 Co-leader of Washington University Chapter of Physicians for Human 
Rights 
2008 Choreographed and Performed First Anatomy Memorial Dance 
